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1.1 Preamble 
1.1.1 Molecular imaging 
The completion of the Human Genome Project lead to the outburst of research related to 
gene and cell based therapies (1). These therapies promise progress for the treatment of 
numerous genetic metabolic diseases, cancers as well as neurological, cardiovascular, 
immunological or inherited disorders. In spite of the effort for several years, no human gene 
therapy product has yet been approved by the Food and Drug Administration (FDA). This 
necessitated the development of modalities to decipher the reasons for successes and failures 
of these therapies by direct visualization of biological processes at the sub-cellular level. The 
available traditional diagnostic methods have limited application in this case. These 
conventional ways are primarily based on the macroscopic observations of morphological 
and physiological changes appearing as a result of underlying molecular processes. However, 
a recent biomedical discipline emerged that allows the possibility to directly evaluate the 
differences at the molecular level in intact living organisms (2). Appropriately designated as 
“Molecular Imaging”, this discipline has been defined as ‘the in vivo characterization and 
measurement of biological processes at the cellular and molecular level’ (3). Other variations 
to the definition are also proposed for the field but all of them emphasize on the same theme 
(4, 5). Apart from gene imaging, molecular imaging proposes the utilization of diverse 
imaging modalities for evaluating molecular events like protein-protein interactions, optimize 
drug therapy and observe their effects at sub-cellular levels, to assess the progression of 
diseases starting at the molecular level and to traffic and target cells in vivo. 
Molecular imaging offers several benefits over routine in vitro or cell culture methods. 
An interesting aspect of molecular imaging is that by using specific probes it can follow 
biological processes in intact living organism using minimum invasive techniques. This, in 
addition, permits repeated measurements on the same object at different time points. Also a 
combination of different imaging modalities could be applied to gain insight into the 
temporal and spatial biodistribution of a specific probe in the midst of complex network of 
several other biological processes. These developments would facilitate the extrapolation of 
observations from whole laboratory animals to use in human scenario. The most widely used 
imaging technologies include radionuclide imaging (positron emission tomography (PET), 
single photon emission computed tomography (SPECT), etc.), optical imaging (fluorescence, 
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bioluminescence), computed tomography imaging (CT) and magnetic resonance imaging 
(MRI) (3, 5) (Fig. 1). Depending on the final application, each of these techniques possesses 
some benefits and some drawbacks. On one hand PET is a highly sensitive method but has a 
poor spatial resolution. Fluorescence imaging is time–efficient but limited by depth 
penetration and MRI offers excellent three-dimensional resolution but needs improvement in 
sensitivity. Recent advancements involve the coupling of two or more techniques leading to 
multi-modality molecular imaging which improves their distinct advantages (4, 6-8). 
 
 
Figure 1. Overview of multiple imaging modalities available for molecular imaging of 
small laboratory animals (A) microPET, (B) microCT, (C) microSPECT, (D) optical 
reflectance fluorescence, (E) microMRI (F) optical bioluminescence image. (adapted 
from Massoud et al. (5). 
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Amongst the various biological imaging techniques, advances in MRI have 
revolutionized the way in which biological processes are being investigated. It offers a 
noninvasive means to chart structure and function with high spatial resolution without use of 
harmful radiations. Through MRI, three-dimensional imaging of soft tissues is performed by 
assessing the amount, flow and environment of water protons in vivo. The signal intensity of 
the image obtained depends on the water content, relaxation times (T1, the longitudinal 
relaxation time and T2, the transverse relaxation time) and/or diffusion characteristics (9). 
MRI is not limited by light scattering, as optical microscopic techniques and offers a 
resolution in the range of tens of μm. However, the low sensitivity of this technique needs 
longer imaging times and therefore, slow acquisition of data, thus compromising the temporal 
resolution. 
The intrinsic signal generated in MR images can be further enhanced by contrast agents 
(CAs) to better visualize regions, tissues and cells that are magnetically similar but 
histologically distinct (10). The effect of CA on the MR signal is indirect as it does not 
appear on the CA but on the surrounding water protons. The efficiency of the CAs depends 
on their relaxivity defined as the increase of the nuclear relaxation rate (the reciprocal of the 
relaxation time) of water protons produced by 1 mmol per liter of CA (expressed in s(-1) 
mmol(-1)L). The number of water molecules in the first coordination sphere, the water 
exchange rate and the rotational correlation time have a strong effect on their relaxivity. 
Based on the changes in T1 and T2 relaxation rates, CAs in MRI have been categorized as 
positive agents, producing increased signal intensity on T1-weighted images, or negative 
agents, showing decreased signal intensity on T2-weighted images, or both (11). T1 CAs 
mainly contain the paramagnetic metal ion gadolinium (Gd) (12, 13) while most of the T2 
agents are based on superparamagnetic iron oxide particles (14). To put in a simpler way, 
images of regions where the CAs are located appear brighter with Gd-based agents and those 
with iron-based agents appear darker. 
As the free metal ion of Gd is toxic, it needs to be complexed to ensure the safety of the 
agent during its passage through the body of the patient. Two of the widely used CAs are the 
acyclic chelator diethylenetriaminepentaacetic acid (DTPA) or the more stable macrocyclic 
chelator 1,4,7,10-tetracarboxymethyl-1,4,7,10-tetraazacyclododecane (DOTA) (Fig. 2) (13). 
The Gd metal ion needs to be loaded into these chelators for use as a CA. As a result of their 
kinetic inertness and thermodynamic stability, they remain chelated in the body and are 
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excreted intact. Based on these chelators, a handful of CAs (like Magnevist®, DOTAREM®, 
etc.) are clinically approved and commercially available but most of them are exogenous, 
restricted to the extracellular space, non-specific and also need to be applied in a 
concentration range between 0.01 to 10 mM. They are marked by unselective biodistribution 
over the extracellular fluid and the resultant contrast is dependent on their tissue permeability 
versus the clearance rate. 
 
Figure 2. Chemical structures of Gd(DTPA) and Gd(DOTA). 
New classes of MRI CAs are gradually emerging in the context of molecular imaging. 
These agents need to be designed for showing higher contrasting ability and improved 
specificity for characterization of cellular and molecular processes. Almost all of the 
available CAs till date have been compiled in an extensive review by Yoo et al. (15). Though 
most MR investigations for molecular imaging were based on iron nanoparticles but the 
issues relating to the metabolic fate of these iron-based agents and retention of their high 
concentrations in the cellular cytoplasm led to the exploration of Gd-based CAs for molecular 
imaging (16, 17). 
1.1.2 Targets for intracellular imaging 
The cell is the most basic unit of life. It is the smallest unit of an organism that has been 
classified as living but is still extremely complicated. The complexity arises as a result of a 
myriad of biological processes simultaneously going on in the cell to maintain its function 
(Fig. 3). These processes, like protein synthesis, cellular metabolism, DNA replication, cell 
signaling, etc., are fundamental and involve intricate cascades of biochemical reactions. In 
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fact, cellular processes are carried out by the combined activity of numerous genes, their 
products, and a variety of other molecules. 
 
Figure 3. The complexity of biological processes essential for proper functioning of a 
cell. (adapted from the webpage of MAGnet, http://magnet.c2b2.columbia.edu/). The 
circles here indicate the collection of biomolecules which are in constant interaction with one another, depicted by 
the dense network of lines, for proper functioning of the cell. 
Interestingly, any of these cellular components from the cellular pool could be recognized 
as targets keeping the final purpose of application in view. The generic cellular targets 
comprise of DNA, messenger RNA and proteins. In drug development, proteins, especially 
receptors and enzymes, have been generally exploited. The major reason for application of 
proteins as targets was related to their large numbers per cell (Table 1). Imaging of protein 
based targets, referred as “downstream imaging”, has been well explored for in vivo 
molecular imaging as it requires little signal amplification (18-20). Apart from the ones 
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already used, there exists a collection of almost ten times more enzymes, receptors, antigens, 
etc. that are still to be tried and tested for application as targets. 
Table 1. Different intracellular imaging targets and their number per cell. (adapted 
from Sharma et al. (21)). 
 
Nevertheless, to be able to directly image gene expression for the understanding of 
genetic defects from the origin, therapy assessment and many more applications, imaging at 
DNA and mRNA level is necessary. Use of DNA as a target, with only two molecules per 
cell (21), requires extraordinary mechanisms for enhancing the signal to noise ratio. 
Fluorescence in situ hybridization (FISH) exists as a method for imaging DNA at cellular 
level. Such technologies and methods still need to be developed for whole body imaging. 
Moreover, monitoring the DNA provides information on genetic alterations and not on its 
expression and normal or abnormal function. 
The copy number for mRNA ranges from a few hundred to few thousand copies in a 
single cell. Although not most favorable for imaging by MR, combinations with amplification 
techniques are being developed to directly image mRNA and obtain information on cellular 
gene expression in normal and diseased conditions. 
1.1.3 Antisense imaging 
7 
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Figure 4. Schematic representation of antisense imaging in the context of cellular 
gene expression, contrasted with imaging of proteins and reporter protein function. 
(adapted from Lewis et al. (22)). 
According to the central dogma of molecular biology, the principal role of mRNA is to 
transfer the genetic information contained in the DNA for translation to the protein level. 
Transcription is the process of RNA synthesis through which information is transferred 
between DNA sequence and a complementary mRNA by formation of Watson-Crick base 
pairs. Any synthetic short oligonucleotide with a sequence complementary to the target 
mRNA is referred as antisense (Fig. 4). The antisense sequence binds to the target and mostly 
inhibits its translation. This concept is being used for antisense chemotherapy to inhibit the 
translation of a defective gene for treatment of various cancers and viral diseases. Antisense 
drug development continues further with a drug (Vitravene, Isis) for the treatment of 
cytomegalovirus-induced retinitis in AIDS patients already approved by the US FDA (23) 
and some more in late-stage development. 
In 1994, Dewanjee et al. presented a pioneer study to image a mouse tumor in vivo using 
a radiolabeled DNA sequence complementary to the initiation code of c-myc oncogene RNA 
(24). Although it is still to be verified, this study suggested the use of labeled antisense 
oligonucleotide analogues for imaging of gene expression and thus the conceptualization of 
antisense imaging (Fig. 4). Due to increased sensitivity, mostly radiolabeling has been used 
for antisense imaging studies (25-27). In spite of various efforts, until date no real-time, 
direct, in vivo imaging has been demonstrated in a conclusive manner. But the field has not 
been dormant and progress has been made to remove some bottlenecks by means of 
development of higher affinity antisense analogues, development of protocols to assess target 
interaction, improved cellular delivery, etc. (22, 28). 
While a direct depiction of antisense targeting is still hard to define even in cell culture, 
most studies rely on indirect evidences. Increased accumulation against different targets and 
in different cell types compared to control suggested an involvement of antisense mechanism 
(29, 30). Another investigation demonstrated that accumulation of probe decreases with 
increasing concentration of (31, 32). This indicates that with increasing dosage binding 
becomes saturated. 
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The first antisense agents used were unmodified phosphodiester DNAs. But their fast 
degradation by nucleases in vivo hindered their use for imaging. The new generation of 
oligonucleotide analogues show improved stability and target binding. By varying the 
backbone of oligomers large variations can be imparted in their properties. DNA 
phosphorothioates show higher biological stability (33) and have been used for antisense 
therapy as they activate RNase H mediated degradation of mRNA. As only 5-6 base pairs are 
involved in duplex formation and therefore have a high possibility of also degrading the non-
target mRNAs, it has been concluded that RNase H-independent analogs would be preferred 
for imaging (28). By introducing an artificial backbone in place of the ribose scaffold of 
DNA and RNA, new analogs have been developed. These analogs bind complementary DNA 
with greater affinity and include peptide nucleic acids (PNA) (34), morpholino (MORF) (35), 
trans-4-hydroxy-L-proline nucleic acid-phosphono nucleic acid (HypNA-pPNA) (36) and 2’-
O-methyl small interfering RNA (siRNA) (37). However, the use of most of these modified 
analogs is limited to laboratories with a monomer synthesis facility as only PNAs and 
MORFs are commercially available. 
As their nomenclature suggests, PNAs contain a neutral peptide backbone instead of the 
negatively charged sugar-phosphate backbone in DNA (38). PNAs have several properties 
that make them favorable for application. The duplexes between PNA/DNA and PNA/RNA 
show higher thermal stability than DNA/DNA or DNA/RNA duplexes (39). The absence of 
charge repulsion between neutral PNA and DNA or RNA leads to a stronger binding between 
them. Also, PNA show a greater specificity to bind to the target sequence and binding occurs 
at low ionic strength where normal DNA binding would not take place. Another advantage of 
their peptide backbone is the resistance to nucleases and proteases, thus, extending their 
lifetime (40). PNAs are being utilized for a multitude of applications (38) but two major 
problems still need to surmounted. The first is the poor solubility in aqueous solution arising 
from the charge-neutral backbone which, therefore, also is related to the length of oligomer 
(39). The second issue is their inadequate cellular uptake leading to a low intracellular 
accumulation of PNAs. This is a serious challenge for in vivo applications and new methods 
need to be investigated to assist the delivery of PNAs across the plasma membrane. 
1.1.4 The plasma membrane 
The cell evolved as a highly organized structure with barriers that define its inside and 
outside. The plasma membrane serves as the boundary of cells and protects it from the 
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surrounding environment. The eukaryotes also contain intracellular membranes that define 
internal organelles like nucleus, mitochondria, lysosomes, etc. Membranes are as diverse in 
structure as they are in function. They are dynamic structures but have a common membrane 
architecture composed of a lipid bilayer with proteins floating in this sea of lipids (Fig. 5). 
The membrane lipids are amphipathic molecules as they contain a hydrophilic polar head 
group pointing out and a hydrophobic moiety forming the core (41). The thickness of most 
membranes is between 60 Å (6 nm) and 100 Å (10 nm). Membranes also contain 
carbohydrates that are linked to lipids (glycolipids) and proteins (glycoproteins). Most cell 
membranes are electrically polarized, such that the inside is negative [typically -60 millivolts 
(mV)]. The membrane potential plays a key role in transport, energy conversion, and 
excitability. 
 
Figure 5: Diagrammatic representation of the plasma membrane. (adapted from an 
online representation under copyright by John Wiley & Sons, Inc.). 
The lipid components of the membrane act as a permeability barrier while the proteins 
permit limited transport and impart selective permeability to the membrane. Membrane 
proteins are embedded in the lipid bilayer, which creates a suitable environment for their 
action. These proteins can be categorized as peripheral or integral based on the difference in 
their dissociability. Peripheral membrane proteins are loosely bound to membranes mainly by 
electrostatic and hydrogen-bond interactions with the head groups of lipids. In contrast, 
integral membrane proteins interact strongly with the hydrocarbon chains of membrane 
10 
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lipids, and are embedded in the lipid bilayer. These embedded proteins are also amphipathic 
with their side chains oriented in hydrophobic and hydrophilic regions of the lipid bilayer. 
Due to their own physicochemical characteristics and the functional characteristics of the 
embedded transmembrane proteins, the plasma membranes are selectively permeable. Their 
structure allows specific molecules to be taken up and unwanted compounds to be removed 
from the cell. All transport across cell membranes occurs by one of the following 
fundamental processes:  
• Passive transport: Through this process, molecules are transported across the 
membrane barrier without spending any energy. Usually small molecules like water, 
oxygen gas and some ions enter into cells by passive transport. The transport is driven 
by a concentration gradient (diffusion) or osmotic gradient (osmosis). Movement of 
ions could be energy independent but assisted by channels (facilitated diffusion). 
• Active transport: This procedure is also used for the transport of small molecules but 
depends upon the expenditure of cellular energy. The active transport can move 
molecules even against a concentration gradient. ATP-dependent pumps are used for 
active transport. 
• Endocytosis and exocytosis: The movement of large sized molecules into 
(endocytosis) or out off (exocytosis) a cell proceeds through a more elaborate system. 
By pinching off or fusing together of vesicles, essential materials for nutritional 
uptake, receptor signaling, neurotransmission, etc. cross the plasma membrane. 
1.1.5 Cellular delivery vectors 
As discussed in the previous sections, neither the imaging moieties nor the targeting 
analogs can permeate the plasma membrane by themselves. Therefore, methods need to be 
developed to transport the conjugates into cells in such a way that their functionality is 
maintained. Perspectives of various techniques established primarily for transport of 
macromolecules have been reported by Stephens et al. (42) and Gao et al. (43). 
Direct transfer assisted by capillary microinjection is widely used and shows high 
efficacy. However, this method is technically demanding and offers no possibility for in vivo 
applications. Another route to deliver into cells is by transient permeabilization of the plasma 
membrane. This methodology involves the formation of pores in the membrane by the action 
of detergents, toxins, UV illumination or short electrical pulses (electroporation). These 
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techniques are cheap, easy to use, show high efficiency and also address large numbers of 
cells. However, their application is limited due to the uncertainty of impact on cellular 
structures and organelles and also lack translation for live animal studies. 
Carrier-mediated transfer is an alternative methodology that makes use of a cell 
permeating carrier to deliver the molecule of interest into target cells. It can easily be adapted 
for use in an in vivo setup. Viral vectors have been extensively investigated to efficiently 
transfer genes into cells (44). In spite of their excellent efficiency, viral vectors suffer from 
disadvantages like immunogenicity and cytotoxicity. Liposome-mediated transfer has been 
extensively used for the introduction of DNA or RNA into cells (45). However, the delivery 
efficiency by this method is low and it is also reported to affect lipid metabolism. 
Another type of carrier that gained popularity over the last 15 years is a class of short 
peptides with the potential to translocate across the plasma membrane of eukaryotic cells (46, 
47). These peptides are commonly designated as cell penetrating peptides (CPPs), protein 
transduction domains (PTDs), or cellular delivery vectors (CDVs) and have been used for 
transmembrane delivery of hydrophilic macromolecules. They usually consist of short, 
typically basic, peptide sequences of 7–34 amino acids in length that are capable of crossing 
the cell membrane either alone or attached to a molecular cargo (48). CPPs could be derived 
from natural sequences like HIV-1 Tat (49) and penetratin (50) or be artificial constructs 
designed by use of important features of natural sequences like polyarginines (51) and 
transportan (52). Table 2 presents a selection of the CPP families, their origin and some 
model cargoes delivered by their assistance. 
Table 2: Selection of representative CPP families and model cargoes. (adapted from 
Foerg et al., (46)). 
Name Origin Sequence Cargo 
Tat family 
   Tat (48-60) HIV-1 protein GRKKRRQRRRPPQQ -galactosidase 
   Oligoarginine Tat derivative Rn Cyclosporin A 
Penetratin family 
   pAntp Antennapedia homeodomain RQIKIWFQNRRMKWKK Polo-box 
   pIsl Isl-1 homeodomain RVIRVWFQNKRCKDKK Biotin/avidin 
Chimeric CPPs 
   Transportan Galanin-mastoparan GWTLNSAGYLLGKINLKALAALAKKIL GalR-1 (antisense) 
   MPG peptides   siRNA  
      P  gp41-SV40 GALFLGFLGAAGSTMGAWSQPKKKRKV Fluorophore 
      P  gp41-SV40 GALFLAFLAAALSLMGLWSQPKKKRKV Fluorophore 
Pep-1 Trp-rich motif-SV40 KETWWETWWTEWSQPKKKRKV Proteins 
12 
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Name Origin Sequence Cargo 
Antimicrobial-derived CPPs 
   Buforin 2 Toad stomach TRSSRAGLQWPVGRVHRLLRK GFP 
   Bac715-24 Bactenecin family PRPLPFPRPG NeutrAvidin 
   SynB(1) Protegrin 1 RGGRLSYSRRRFSTSTGR Doxorubicin 
Other CPPs 
   pVEC Murine VE-cadherin LLIILRRRIRKQAHAHSK Fluorophore 
   VP22 Viral protein (HSV-1) DAATATRGRSAASRPTE- GFP 
  -RPRAPARSASRPRRPVE  
hCT-derived peptides 
   hCT(9-32) Human calcitonin LGTYTQDFNKFHTFPQTAIGVGAP GFP 
   hCT(9-32)-br Human calcitonin, SV40 LGTYTQDFNKFHTFPQTAIGVGAP GFP 
  AFGVGPDEVKRKKKP-NH2  
SAP Modified maize VRLPPP-VRLPPP-VRLPPP Fluorophore 
Protamin Salmon roe Mixture of protamin 1-4 Fluorophore 
Although diverse in sequence, CPPs share some characteristics. Almost all known 
penetrating peptides have a dependence on cationic amino acids, primarily arginine and 
lysine. It has been established that guanidine head groups are a critical structural feature for 
interaction with the plasma membrane and for translocation (53). The uptake is also shown to 
be independent of the involvement of receptors. Delivery of penetratin (54, 55) and HIV-1 
Tat (56) was unaffected by the retro-inverso sequence or when these peptides were composed 
entirely of D-enantiomers, indicating that the process is not mediated by receptors. Several 
investigations have also been conducted to elucidate the route of entry of CPPs into cells (57, 
58). A variety of internalization mechanisms seem to be operating for breaching the 
membrane barrier (Fig. 6). 
 
Figure 6. Possible mechanisms of uptake across the plasma membrane (adapted 
from Stewart et al. (47)). 
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Like any other methodology, CPP-assisted delivery also has some limitations. These 
peptides could induce immunogenicity and toxicity by affecting fundamental cellular 
functions (59-61). Also attention needs to be paid at the technical level for proper evaluation 
of delivery. Fixation of cells has been reported to induce artifactual intracellular 
redistribution of CPPs (62, 63). In addition, careful detection is needed to separate the surface 
bound cargo from the internalized one (63). 
1.2 Aims of the study 
Owing to its high spatial resolution, MRI is an optimal method for imaging complex 
biological processes. There have been reports on conjugation of exogenous MR contrast 
agents with translocation peptides and observation of intracellular contrast changes in labeled 
cells (64-67). For the purpose of molecular imaging, the first and so far the only study was 
reported by Heckl and co-workers in 2003 (68). Using MRI and fluorescence, they observed 
a specific accumulation of a c-myc specific PNA in vitro as well as in vivo. However, no 
further application of the same or any new study has been reported. As a modified acyclic 
Gd-based chelator was used in this report, its stability at the low pH environment like 
lysosomes in the cell is uncertain. 
Improved MRI based intracellular agents for molecular imaging could be designed by 
introducing more stable macrocyclic CAs and more efficient CPPs. The aim of the present 
project was to develop intracellular MR contrast agents targeted to image specific mRNA. As 
was necessitated by the results obtained, novel agents for membrane translocation were also 
developed. 
The central hypothesis of the projects was that mammalian cell lines mimic in vivo 
conditions, physiologically as well as biochemically. Assays developed using these cell lines 
could serve as a primary screen for the identifying an optimal molecule before testing in vivo. 
1.2.1 Evaluation of mRNA-targeting intracellular MR Contrast Agents 
Molecular imaging of cells and cellular processes can be achieved by tagging 
intracellular targets such as receptors, enzymes or mRNA. In the first part of the thesis we 
began with the screening of the optimal derivative of HIV-1 Tat peptide for intracellular 
delivery of MRI CAs. Seeking to visualize the presence of specific mRNAs by MR imaging, 
we evaluated peptide nucleic acids (PNA) conjugated with Gd-based MR contrast agents 
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using cell-penetrating peptides for intracellular delivery. An anti-sense to the mRNA of 
DsRed2 protein was used as a proof-of-principle. The conjugates were produced by 
continuous solid phase synthesis followed by chelation with Gd. To begin with, in vitro cell-
free assays were established to verify the specificity of the PNA towards target. The cellular 
uptake of these intracellular targeted CAs was confirmed by fluorescence microscopy and 
spectroscopy. Studies were performed in target-deficient as well as target-containing cell 
lines. Cells labeled with these targeted CAs were also imaged by MRI to observe the 
difference contrast enhancement. Finally, the biodistribution of the CA was confirmed in 
C57BL/6 mice. 
The accomplishments from this part of the project have been compiled in the 
following two publications: 
• W. Su, R. Mishra, J. Pfeuffer, K.H. Wiesmüller, K. Ugurbil and J. Engelmann: 
Synthesis and Cellular Uptake of a MR Contrast Agent Coupled to an Antisense 
Peptide Nucleic Acid - Cell Penetrating Peptide Conjugate. Contrast Media & 
Molecular Imaging, 2, 42-49 (2007). 
• R. Mishra, W. Su, R. Pohmann, M. G. Sauer, J. Pfeuffer, K. Ugurbil and J. 
Engelmann: Cell Penetrating Peptides and Peptide Nucleic Acid Coupled MRI 
Contrast Agents: Evaluation of Cellular Delivery and Target Binding. Bioconjugate 
Chemistry, 20, 1860-1868 (2009). 
1.2.2 Development of a novel cysteine-rich Cytosolic Localizing Peptide CyLoP-1 
The shortcomings of the first project initiated the development of novel CPPs that not 
only penetrate the plasma membrane but also release the cargo into the cytosol for better 
interaction with targets located in the cytoplasm. In the second part of the thesis, numerous 
derivatives of a putative nuclear localization sequence from the snake toxin Crotamine were 
evaluated. Based on fluorescence spectroscopy and microscopy, cellular delivery and 
distribution of these peptides was tested. These extensive structure-activity-relationship 
studies led to the identification of a novel cysteine-rich CPP that distinctly localized in the 
cytosol. Referred to as CyLoP-1, the factors responsible for the distribution in the cytoplasm 
were analysed by observing uptake under different conditions and in various cell types and 
investigating the effect of CyLoP-1 on cells. 
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The accomplishments from the second part of the project have been compiled in the 
following two manuscripts: 
• R. Mishra, D. Jha, K. Ugurbil and J. Engelmann: Novel Cysteine Rich Cell 
Penetrating Peptide CyLoP-1: Understanding the delivery in cytosol. (In preparation). 
• D. Jha, R. Mishra, K. Ugurbil, M. E. Maier, K. H. Wiesmüller and J. Engelmann: 
Development of a Novel Cysteine Rich Cell Penetrating Peptide: Efficient Uptake and 
Access to Cytosol. (In preparation). 
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2.1 Introduction 
Remarkable progress in the understanding of cellular processes, both at the molecular and 
genetic level, has been made by the development of molecular-biological assays. Despite this, 
a myriad of questions about biological processes under normal as well as diseased conditions 
remain. Of late, the new field of molecular imaging has evolved with the intent to translate 
knowledge gained from in vitro systems into studies of complete biological systems. 
Molecular imaging aims at non-invasive visualization of biological processes amid the 
complex networks and interactions in the intact individual (2-4). Imaging modalities being 
extensively used for this purpose are positron emission tomography (PET), single-photon 
emission computed tomography (SPECT), optical imaging using fluorescence or 
bioluminescence, and magnetic resonance imaging (MRI) (5, 69). 
MRI is a powerful tool in clinical diagnostics as well as for understanding developmental 
and biological processes. It visualizes the differences in tissues and organs, as well as 
between normal and pathological states as a function of water concentration and relaxation 
times, T1 and T2, in a given volume element (9). The main advantages of MRI over other 
imaging techniques are its high spatial and temporal resolution, the absence of harmful 
ionizing radiation and the ability to non-invasively scan entire organisms in one, two or three 
dimensions. The intrinsic contrast of MR images can be augmented by the use of contrast 
agents (CAs). Chelated paramagnetic metal ions, in particular gadolinium, have been 
primarily used as T1-based CAs to increase the contrast in MR images (16). An assortment of 
gadolinium-based CAs is commercially available and these agents are frequently employed 
for clinical diagnosis. Though, their utility is based on enhancement of anatomical 
information due to differential biodistribution in the body (70, 71). For example, in the brain, 
these agents do not cross the blood brain barrier (BBB) except when the BBB is broken 
because of pathology; as such, they lack specificity. Advancing from these agents towards 
extracellular targeting by conjugation of CAs to certain proteins and especially to monoclonal 
antibodies or antibody fragments has been explored. Most of the investigations were related 
to the development of tumor-specific agents (18-20, 72, 73). 
However, numerous intracellular imaging targets are available and these can be tagged to 
provide molecular information. Regardless of the low number of targets at DNA level, 
molecules at RNA (over-expressed) or protein level could serve as potential targets (3). 
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Moreover, since the completion of human genome sequence, there has been considerable 
research interest in assessing gene expression through non-invasive molecular imaging 
approaches. Considering that an oligodeoxynucleotide (ODN) with more than 12 bases could 
target a unique sequence in the whole human genome (74), ODNs are good templates for the 
development of new targeted MR imaging probes with high specificity. 
Natural ODNs cannot be directly used for molecular imaging because they are rapidly 
degraded in vivo by endo- and exonucleases (25). Furthermore, ODNs can cause degradation 
of the target mRNA by RNAse H. A number of novel oligonucleotide analogues, designed 
for improved stability, target binding, and antisense activity, have been synthesized and 
evaluated in vitro and in vivo (75-77). Modifications include morpholino, phosphorothioate, 
phosphoroamidate, methylphosphonate, 2’- or 3’- modifications, 2’- 4’ bridges, and complete 
replacement of the backbone with an amide backbone (peptide nucleic acid or PNA). PNA is 
a DNA mimic containing a pseudopeptide backbone that makes it extremely stable in 
biological fluids (78). Despite the radical difference in the chemical composition of the 
backbone, PNA not only retains but also improves the hybridization characteristics of DNA 
and RNA (79). In most cases, PNA oligomers with mixed base sequences form duplexes (by 
Watson-Crick base-pairing) with complementary DNA and RNA with higher thermal 
stability than corresponding DNA-DNA or DNA-RNA complexes and without sacrificing 
sequence specificity. These qualities make PNA a leading agent among ‘third generation’ 
antisense and antigene agents. Recent work has shown that PNA can be used as molecular 
hybridization probes (80), nuclear imaging tracers (81), and to control gene expression and 
splicing (82). 
Direct imaging of mRNA can provide information on cellular gene expression patterns 
and may have the potential to detect molecular changes in disease states at relatively early 
stages, providing opportunities for pre-emptive therapeutic interventions (22). To be useful as 
a probe, an antisense PNA must target a unique mRNA sequence in the objective cells. In 
order to ensure good detection sensitivity and selectivity for MR imaging, the targeted 
mRNA should be highly abundant in cells. Therefore, as a proof of principle we chose the 
mRNA of DsRed2, a variant of the red fluorescent dsRed protein as target. The gene for 
dsRed protein, originating from a coral of the Discosoma genus (83), is widely used as a 
transfection marker in molecular biology. Thus, there are increasing numbers of transgenic 
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cell lines expressing the dsRed and its more stable and better soluble variant DsRed2 protein, 
which can be used later as models for in vivo studies.  
However, using antisense PNA as a molecular imaging probe has a major obstacle in that 
they are not able to penetrate biological membranes. In 2003, Heckl, et al (68) reported the 
first results on an intracellular MR contrast agent, composed of a gadolinium complex, a c-
myc-specific PNA sequence and a trans-membrane carrier peptide, showing the potential of 
peptide-based delivery to penetrate through the cell membrane. Whether improvements on 
this strategy can be achieved using different carrier peptides and/or contrast agent moieties 
remains an important question. Researchers have resorted to several other cargo delivery 
techniques such as using cationic lipids and liposomes (84), nanoparticles (85), and direct 
conjugation with monoclonal antibodies (86) or peptides (87), etc. to overcome the obstacle 
of plasma membrane. However, cell-penetrating peptides (CPPs) emerged as an extremely 
efficient way to overcome this most challenging delivery barrier. They are a class of short 
peptides that have been reported to import a wide range of cell-membrane impermeable 
cargos into cells (88-91). CPP-oligonucleotide conjugates, unlike oligonucleotide complexes 
with cationic lipids or polymers, are of relatively modest molecular size. Thus, they are more 
likely to evade uptake by the phagocytes of the reticuloendothelial system and to attain a 
widespread biodistribution subsequent to in vivo administration. Amongst the large variety of 
CPPs available, Tat peptide (derived from HIV-1 Tat protein) is the most intensively studied 
and has high delivery ability for vast variety of cargos (92). Thus far, there is no consensus 
on the mechanism of uptake of CPPs and the maintenance of functionality of cargos after 
delivery. Variance is also reflected by differences in reported labeling techniques, non-
standardized protocols regarding uptake evaluation, and discrepancies caused by the use of 
different cellular model systems (93-95). 
Keeping these issues in mind, we began our pursuit for evaluating the most appropriate 
CPP, selected from three derivatives of the well-established CPP HIV-1 Tat peptide, to 
deliver CA into cells. The cargo attached to the CPP was a gadolinium-loaded chelator, 
1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (Gd-DOTA), for MR imaging, 
and fluorescein isothiocyanate (FITC) for optical imaging (Fig. 7). 
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Figure 7. Schematic structures of CPP and PNA conjugated Gd(DOTA) based 
intracellular contrast agents. All amino acids are represented in a single letter code where R: arginine, 
K: lysine, Q: glutamine and O: ornithine. D-amino acids are represented in lower case. The PNA building blocks 
are represented as a: adenine, t: thymine, g: guanine and c: cytosine. 
Using the selected CPP, a targeting PNA (either targeting DsRed2 mRNA or a non-sense 
sequence) was introduced into the above-mentioned conjugate (Fig. 7). The objective was to 
develop and synthesize PNA targeting intracellular MR contrast agents. Initial cell biological 
assays were made on normal NIH 3T3 mouse fibroblasts to test the internalization of these 
compounds into cells and their biocompatibility using MR and fluorescent optical imaging 
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techniques. Since the DsRed2 protein was used as a model system, the proof-of-principle was 
examined in a transgenic DsRed2-expressing cell line (96). The aim was to assess the 
intracellular delivery and distribution of these larger molecules in the presence or absence of 
target mRNA in the cells. The ability of the agents to bind with targets in a cell-free in vitro 
system, as well as by labeling cells, was also evaluated. In the end, the biodistribution of the 
CA containing the anti-sense PNA will also be briefly presented here using fluorescence for 
detection. 
2.2 Materials and methods 
2.2.1 Chemical synthesis 
All CPP conjugates and contrast agents were obtained by in-house synthesis performed 
by colleagues in the Chemistry section of the Chemical Biology Group, High-Field Magnetic 
Resonance Center, Max Planck Institute for Biological Cybernetics. In brief, the following 
steps were followed to synthesize Gd(DOTA) conjugates with CPPs (Scheme 1) and PNA 
(Scheme 2). 
2.2.1.1 Peptide synthesis 
All the CPPs used in this work were chemically synthesized by solid-phase peptide 
synthesis with Fmoc/tBu-strategy on a Heidolph Synthesis 1 synthesizer (Germany) using 
polystyrene-based Wang resin as solid support. 
2.2.1.2 PNA synthesis 
Synthesis of anti-dsRed-PNA (tcc gtg aac ggc) and nonsense PNA (gtt cag agt cta) were 
performed in a manual reaction synthesizer. Fmoc/Bhoc chemistry was used to couple PNA 
building blocks through an AEEA spacer to D-Tat(57-49) by a continuous solid phase synthesis 
scheme. 
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Scheme 1. Synthesis of CPP conjugated MR contrast agents by continuous solid-
phase synthesis scheme. 
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Scheme 2. Synthetic scheme followed for making PNA conjugated MR contrast 
agent. Reagents and conditions: (i) Fmoc-AEEA-OH, HATU, DIEA, DMF; (ii) Fmoc/Bhoc protected monomers,  
24 
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HATU, DIEA, DMF; (iii) Fmoc-Lys(Dde)-OH, HATU, DIEA, DMF; (iv) DOTA-(tBu)3-OH, HATU, DIEA, DMF, 12 h; 
(v) FITC, DIEA, DMF, 7 h; (vi) TFA: TIS: H2O (95:2.5:2.5), 4 h; (vii) GdCl3.6H2O, 60˚C, 12 h. 
2.2.1.3 Conjugation of DOTA and labeling with FITC 
On completion of the PNA sequence, a Fmoc and Dde protected Lys residue was 
conjugated. DOTA tris(tert-butyl) ester was synthesized in-house (97) and coupled to the Lys 
on its α-NH2 group after deprotection of Fmoc. Next FITC was conjugated with the ε-NH2 
group of the Lys. 
2.2.1.4 Chelation with gadolinium 
The conjugates were cleaved off the resin and loaded with gadolinium using GdCl3.6H2O 
under mild conditions for 12 h. The pH was periodically checked and adjusted between 6.0-
7.0 using a solution of Na2CO3 and HCl as needed. 
2.2.1.5 Purification and characterization 
Gd-DOTA-conjugated CPPs and PNAs were analyzed and purified using analytical and 
semipreparative RP-HPLC on a Varian PrepStar Instrument (Australia) equipped with 
PrepStar SD-1 pump heads. The purification was performed both before and after gadolinium 
loading. The reaction mixture was dialyzed (Float-A-Lyzer, cellulose ester membranes, 
MWCO: 2,000; Spectrum Laboratories, Inc.) to remove other impurities and finally the 
solution was lyophilized till used. Characterization was performed by ESI-MS on Agilent SL 
1100 Series LC/MSD Trap system (Agilent, Germany). 
2.2.2 Concentration estimation 
Peptide conjugates were dissolved in MilliQ water to obtain a 10 mM solution by weight. 
For the determination of the real concentration, these stock solutions were diluted 1:100 in 
Dulbecco’s Modified Eagle's Medium (DMEM; Biochrom AG, Germany). The absorbance 
of the solutions was measured in a multiplate reader (BMG Labtech, Germany) at 485 nm 
with ratiometric correction of turbidity at 690 nm. The concentrations of the stock solutions 
were calculated after background correction assuming εcarboxyfluorescein 485 nm=81,000 
l/(mol·cm) and all further dilutions were done according to this calculated concentration. 
2.2.3 Cell culture 
NIH 3T3 cells were obtained from DSMZ, Germany, CCL-11 fibrosarcoma cells from 
ATCC, USA, and the DsRed2 protein-expressing fibrosarcoma CCL-11 cell line (DsRed 
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cells) was a kind gift of Dr. Marna Ericsson, University of Minnesota, USA. NIH 3T3 mouse 
fibroblasts were cultured as a monolayer at 37°C with 10% CO2 in DMEM supplemented 
with 10% fetal bovine serum (FBS), 4 mM L-glutamine, 100 µg/mL streptomycin and 100 
U/mL penicillin (all purchased from Biochrom AG, Germany). Cultures of DsRed cells and 
the parent cell line CCL-11 were maintained at 37°C with 5% CO2 in NCTC 135 medium 
(Sigma, Germany) supplemented with 10% heat-inactivated fetal horse serum, 2.2 g/L 
sodium bicarbonate and pH adjusted to 7.2. All cells were passaged by trypsinization with 
trypsin/EDTA 0.05/0.02% (w/v) in phosphate-buffered saline (PBS; Biochrom AG, 
Germany) every second to third day. 
2.2.4 In vitro binding assay 
2.2.4.1 Cell-free FITC-based immunoassay 
The in vitro proof of specific binding of anti-dsred CA was obtained in a cell-free FITC 
immunoassay with slight modifications (98). A synthetic 45-mer single-stranded 
deoxynucleotide sequence (5’-CTC GAA CTC GTG GCC GTT CAC GGA GCC CTC CAT 
GCG CAC CTT GAA GCG CAT GAA CTC CTT GAT-3’) containing the complementary 
target site of anti-dsred CA was obtained commercially (Eurofins MWG, Germany). The 
target ODN sequence extended by a 12-mer C linker was immobilized on DNA binding 
plates (Corning, Germany) in DNA binding buffer (50 mM sodium phosphate, 1 mM EDTA, 
pH 8.5) at 4°C for 24 h. After washing off excess ODN with PBS, the plates were incubated 
with blocking buffer (DNA binding buffer containing 10% FBS and 3% bovine serum 
albumin (BSA)) for 2 h at 37°C. Following a PBS wash, incubation with 16 nM of either 
anti-dsred CA or non-sense CA in 10 mM sodium phosphate, pH 6.5 was performed. For 
hybridization, the binding temperature was maintained at 60°C for 1 h and then slowly 
decreased to 37°C for another 1 h. The plates were left overnight at room temperature. The 
following day, plates were washed 3 times for 5 min each with wash buffer (PBS containing 
0.01% Tween). Incubation with an anti-FITC-horseradish peroxidase (HRP)-conjugated 
antibody (Invitrogen, Germany) was carried out. Subsequent to thorough PBS washing to 
remove unbound antibody, the signal was developed with tetramethyl benzidine for 30 min at 
room temperature and absorbance was measured at 650 nm in multiplate reader (BMG 
Labtech, Germany). Experiments were run at least three times for each CA with two 
replicates. Statistical analysis was performed by Student’s t-test. P values < 0.05 were 
considered significant. 
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2.2.4.2 Gel retardation assay 
The specificity of interaction between the anti-sense PNA and target sequence after pre-
gel hybridization was verified by gel retardation assay (99). The aforementioned 45-mer 
single-stranded deoxynucleotide sequence selected from the DsRed2 cDNA was obtained 
commercially (Eurofins MWG, Germany). This sequence contained a stretch of bases 
complementary to the anti-sense sequence used in the anti-sense CA. The anti-sense CA or 
non-sense CA (10 pmol) were incubated with the synthetic 45-mer single-stranded 
deoxynucleotide (12.5 pmol) in hybridization buffer (12.5 mM Tris buffer, pH 8 containing 
2.5 mM sodium chloride, 0.5 mM magnesium chloride and 0.05 mM dithiothritol (DTT)). 
This pre-loading hybridization was performed at 60°C for 1 h followed by a gradual 
reduction to room temperature. The samples were then run on 8% native acrylamide gel and 
subjected to electrophoresis in running buffer (200 mM Tris-acetate buffer, pH 8.3, 1 mM 
EDTA). Silver staining was used to detect the mobility of the DNA on the gel. 
2.2.5 Cellular uptake assay 
Internalization experiments on cells were performed in 96 well microplates. At 70-80% 
confluency, cells were incubated with different concentrations of peptide-coupled CAs in 
complete culture medium for additional 18 h at routine culture conditions. After incubation, 
the labeling CA were removed and cells were incubated with Bisbenzimid 33342 (Hoechst 
33342), a nuclear stain, in order to estimate the cell number. Extracellular fluorescence was 
quenched by incubation with cold trypan blue (0.05% (w/v) in PBS) for 3 min followed by 
repeated washes with HBSS (100). Cell-related FITC fluorescence (Ex 485 nm/Em 530 nm) 
and cell number (Ex 346 nm/ Em 460 nm) were evaluated in a multiplate reader. Experiments 
were run at least three times for each CA with six replicates. Statistical analysis was 
performed by ANOVA with Tukey’s post test. P values < 0.05 were considered significant. 
2.2.6 Microscopy 
The cells in plates processed for fluorescence spectroscopic measurement, as mentioned 
above, were used for complementary fluorescence microscopy. Microscopy was performed 
without fixation of cells using a Zeiss Axiovert 200 M microscope (Germany) with an LD 
Plan NeoFluor 40X objective. For high resolution microscopy, 5 × 105 cells/mL were 
cultured on channel slides (Ibidi, Germany) for 24 h. Then cells were incubated with CA in 
culture medium for another 18 h under normal culture conditions. These cells were subjected 
to nuclear staining and trypan blue quenching followed by extensive washing with HBSS. 
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Images were made using a Zeiss Plan APOCHROMAT 63X/1.4 oil DIC objective. OptiGrid 
(Improvision, England), a structured light device, was used for acquiring images of confocal 
quality and Volocity Acquisition and Visualization software (Improvision, England) was 
used for high speed image capture and high resolution rendering of data sets as images or 
movies. The imaging conditions were kept constant for the observation of all the different 
samples. Cellular localization and distribution of the CA was observed by irradiating with 
blue light (Ex 470/40 nm) and observing at Em 525/50 nm. Apart from FITC fluorescence, 
the nuclear labeling by Hoechst was observed by Ex 365/15 nm and Em 460/50 nm and 
trypan blue fluorescence viewed by Ex 535/50 and Em 645/75 nm. Also phase contrast 
images with differential interference contrast (DIC) microscopy of the same area were made 
to observe if the cells maintain their normal morphology in the presence of CAs. 
2.2.7 MR measurement  
2.2.7.1 Relaxivity measurement of contrast agents in solution 
Different concentrations (5 μM, 10 μM, 15 μM, 20 μM, 30 μM, 40 μM) of Gd(DOTA) 
conjugates were prepared in aqueous solution for relaxivity measurement of 1 ml aliquots in 
1.5 mL Eppendorf tubes. The protocol was further standardized for high throughput 
measurement in 96well plates requiring only 175 μl of sample.  
The measurement of the relaxation rates R1 and R2 (longitudinal and transverse relaxation) 
of Gd-complexes were performed at 7T (300 MHz) on a vertical 7T/60 cm MRI Biospec 
system (Bruker Biospin, Germany) or 3T (123 MHz) human MR scanner (MAGNETOM 
Tim Trio, Siemens Healthcare, Germany). 
2.2.7.2 In vitro MR measurement in cells 
For MR imaging of cells, exponentially growing cells were labeled with different 
concentrations of CAs in 175 cm2 tissue culture flasks for 18 h. After repeated washes with 
HBSS, cells were trypsinized, centrifuged and re-suspended in 1.5 mL Eppendorf tubes at 2 × 
107 cells for DsRed and CCL-11 in 500 µL complete medium. Cells were allowed to settle 
before MR measurements. Tubes with medium only and cells without CA were used as 
controls. 
MR imaging of the cell pellets at room temperature (~21 ˚C) was performed on a 3 T 
(123 MHz) human MR scanner (MAGNETOM Tim Trio, Siemens Healthcare, Germany), 
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using a 12-channel RF Head coil and slice selective measurements from a slice with a 
thickness of 1 mm positioned through the cell pellet. 
All MR measurements were performed by Dr. Rolf Pohmann, High-Field Magnetic 
Resonance Center, Max Planck Institute for Biological Cybernetics using the following 
parameters. T1 was measured using an inversion-recovery sequence, with an adiabatic 
inversion pulse followed by a turbo-spin-echo readout. Between 10 and 15 images were 
taken, with the time between inversion and readout varying from 23 ms to 3000 ms. With a 
repetition time of 10 s, 15 echoes were acquired per scan and averaged six times. For T2, a 
homewritten spin-echo sequence was used with echo times varying from 19 ms to 1000 ms in 
about 10 steps and a repetition time of 8 s. Diffusion sensitivity was reduced by minimizing 
the crusher gradients surrounding the refocusing pulse. All experiments scanned 2562 voxels 
in a field-of-view of 110 mm in both directions resulting in a voxel volume of 0.43 × 0.43 × 1 
mm3. 
Data analysis was performed by fitting to relaxation curves with self-written routines 
under MATLAB 7.1 R14 (The Mathworks Inc., United States). The series of T1 and T2 
relaxation data were fitted to the following equations: 
a) T1 series with varying t = TI: S = S0 (1 - exp(-t / T1) + S(TI = 0) exp(-t / T1). 
b) T2 series with varying t = TE: S = S0 exp(-t / T2). 
Nonlinear least-squares fitting of three parameters S0, S(TI = 0), and T1/T2 was done for 
manually selected regions-of-interest with the Trust-Region Reflective Newton algorithm 
implemented in MATLAB. The quality of the fit was controlled by visual inspection and by 
calculating the mean errors and residuals. 
2.2.8 Biodistribution study 
C57BL/6 mice were used to study the in vivo distribution of anti-dsred CA. The CA was 
injected intravenously via the tail vein at a dose of 10 µmol/kg in 100 µL saline. An 
equivalent volume of saline was injected into the control animal. After 20 min, animals were 
sacrificed and biodistribution assessed. Tissues harvested included lungs, liver, spleen, 
kidney, heart, bladder, and brain. All tissues were rinsed with PBS to remove blood or hair 
and a slice of arbitrary thickness from each tissue was placed on a glass slide for microscopic 
observation. Microscopy was performed using a Zeiss EC Plan-NEOFLUOR 20x/0.5 
objective. Fluorescence and bright field images of the tissues were obtained and observed for 
CA related FITC fluorescence. 
 Chapter 2: mRNA targeted contrast agents 
30 
2.3 Results 
2.3.1 Evaluation of optimal CPP 
The Gd-DOTA-Lys(FITC) conjugates of L-Tat(49-57) (L-Tat CA), D-Tat(57-49) (D-Tatinv CA) 
and Orn-D-Tat(57-49) (substitution of the glutamine residue with ornithine) (Orn-D-Tatinv CA) 
were synthesized in-house (101) (Fig. 1). Peptide segments were synthesized by an on-line 
solid-phase synthesis scheme. Using an additional lysine as linker, DOTA tris(tert-butyl) 
ester was coupled on its α-NH2 group and FITC on the ε-NH2 group. The final gadolinium-
loaded compounds were used to label cells. Fluorescence spectroscopy was applied to assess 
cellular uptake by FITC fluorescence and toxicity by nuclear DNA content estimation after 
staining with Hoechst 33342.  
Of the three sequences tested, Orn-D-Tat(57-49) was the most efficient in delivering the 
conjugates across the plasma membrane (Fig. 8). However, its uptake was accompanied by a 
very high toxicity, thus limiting its exploitation. Our results did not reveal noteworthy 
difference in the uptake of conjugates with L-Tat(49-57) or D-Tat(57-49) both of which had 
negligible toxicity (although D-Tat(57-49) has been reported to be a more efficient transporter 
for other cargos (102)). The D-form of the amino acids has been reported to show higher 
metabolic stability and almost no enzymatic degradation. Thus, we chose D-Tat(57-49) as the 
CPP for experiments on further coupling of PNA sequences together with Gd-DOTA and 
FITC to obtain bimodal targeting agents. 
The results of MR measurement of CPP conjugated Gd chelates gave similar T1 relaxivity 
(r1) values for L-Tat CA (7.1 mM-1 s-1) and Orn-D-Tatinv CA (7.1 mM-1 s-1) while higher 
relaxivity was measured for D-Tatinv CA (14.2 mM-1 s-1). This high relaxivity was 
consistently reproduced over several batches synthesized and subjected to variety of 
purification methods to get rid of free Gd. The standard value for DOTA loaded with Gd is 
reported to be between 3 - 4 mM-1 s-1 while of Gd-DTPA-(Arg)8 is 6.8 mM-1 s-1 at 3T (66). 
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Figure 8. CA-related fluorescence measured by fluorescence spectroscopy in NIH 
3T3 embryonic mouse fibroblast cells. Cells were incubated with contrast agents at a concentration 
of 20 µM in complete medium for 18 h. External fluorescence was quenched with trypan blue and subsequent 
washes with HBSS. Values are means ± SEM, n=3 with six replicates each. 
2.3.2 Design and synthesis of mRNA-targeted CA 
PNA was selected to target unique mRNA sequences. These polyamide nucleic acids are 
reported to be resistant to enzymatic cleavage in biological fluids and hybridize with DNA or 
RNA with high specificity and affinity (38). As per the base pairing rule, these PNAs could 
bind sequences in cellular mRNA and, therefore, serve as high affinity probes for molecular 
imaging. Although most mRNAs are expressed at low copy numbers under normal conditions 
(50-1000 per cell at any particular time point), these numbers increase many-fold in certain 
situations like disease or stress (3). The use of PNA for imaging specific mRNA could 
potentially serve for early detection of anomalies by monitoring molecular processes. 
Because PNAs have poor cellular uptake, they need to be coupled to delivery agents such as 
CPPs in order to pass through the biological membrane and interact with the intracellular 
target (103). 
The intention of our study was to design a multi-modal probe by the use of a facile 
building block approach. The blocks could easily be altered according to the target 
requirement without significant modification in the synthetic scheme. The molecule 
eventually designed contained MR and optical imaging moieties linked to PNA for targeting 
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and CPP for intracellular transport. In order to establish a proof-of-principle, mRNA from a 
variant of the red fluorescent protein, DsRed2, was chosen as the target. Through a BLAST 
database search, a 12mer anti-sense sequence (tcc gtg aac ggc, anti-dsred) specific to the 
DsRed2 mRNA was identified (104). Another sequence (gtt cag agt cta) that did not 
correspond to any known mammalian gene was selected as the non-sense control sequence 
(104). 
Two PNA-containing conjugates, anti-dsred CA and non-sense CA were synthesized 
using the same synthetic scheme as reported in detail before (104) (Fig. 1). The chelation of 
gadolinium in the macrocyclic chelator was confirmed by relaxivity measurements of CA in 
aqueous solutions. The relaxivity values for both the CAs (2.8 ± 0.3 mM-1s-1 for anti-sense 
CA and 4.3 ± 0.2 mM-1s-1 for non-sense CA) were corresponding with values for compounds 
with one DOTA complexed gadolinium.  
2.3.3 In vitro proof for binding specificity of anti-sense CA 
The hybridization properties of PNA are crucial for specific antisense targeting. It is 
established that oligonucleotides of 12 or more bases are adequate for targeting unique 
genomic sequences (74). The targeting specificity of anti-dsred CA in comparison to non-
sense CA was determined in vitro using a synthetic single-stranded ODN sequence (45-mer) 
as described in Experimental Procedures. Significant specific binding of the anti-sense CA to 
the synthetic target was observed (Fig. 9a). The non-sense counterpart almost completely 
failed to bind, such that the hybridization signal obtained can be mainly ascribed to specific 
binding. Thus, in vitro studies clearly demonstrated the applicability of the selected anti-sense 
PNA sequence for mRNA targeting. Gel retardation studies further verified the specific 
binding affinity of the anti-sense CA compared to the non-sense CA (Fig. 9b). A retarded 
mobility only of the synthetic single-stranded DNA hybridized with the anti-sense PNA was 
observed, while DNA incubated with non-sense PNA showed no change in mobility in 
comparison to unhybridized DNA. 
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Figure 9. In vitro binding efficacy of anti-dsred and non-sense CA using (a) FITC 
based immunoassay and (b) gel retardation assay. For the immunoassay synthetic single-
stranded target DNA was immobilized on DNA binding plates and hybridization was performed with anti-dsred 
and non-sense CA, followed by extensive washing to eliminate non-specific binding. Detection was performed by 
anti-FITC-HRP-conjugated antibody. Gel retardation of the mobility of target ODN was detected by silver staining 
after hybridization with anti-sense CA. 
2.3.4 In vitro fluorescence studies in 3T3 cells 
To determine whether these synthesized PNA-peptide conjugates are internalized into 
immortalized cells and to evaluate the distribution of the compounds in sub-cellular 
compartments, fluorescence spectroscopy and fluorescence microscopic studies were 
performed with both contrast agents on 3T3 mouse embryonic fibroblasts.  
The results of fluorescence spectroscopy (Fig.10a) showed that both contrast agents could 
enter efficiently into 3T3 cells and in a concentration dependent manner from 0.5 μM to 5.0 
μM. But at concentrations higher than 5.0 μM, the cytotoxicity of these compounds increased 
dramatically (data not shown). Therefore, further experiments were performed at 
concentrations below 5.0 μM. No significant differences between the two compounds were 
observable, as expected for a cell line without any target mRNA. 
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Figure 10. Cell internalization of anti-dsred and non-sense CA into 3T3 cells 
evaluated by (a) fluorescence spectroscopy and (b) microscopy. Cells were incubated with 
contrast agents at various concentrations in complete medium for 18 h. External fluorescence was quenched with 
trypan blue and subsequent washes with HBSS ; values are means ± SEM, n=3-10 with six replicates each, bar 
represents 20 µm. 
Fluorescence microscopy imaging (Fig. 10b) demonstrated that the anti-dsred CA (green) 
could enter cells and was located predominantly in vesicles around the nucleus (blue) 
whereas no uptake into the nucleus was observed. 
2.3.5 In vitro MR studies in 3T3 cells 
Cellular uptake of the synthesized contrast agents were also confirmed by in vitro MR 
studies at 300 MHz. After loading with anti-dsred CA, the relaxation rate R1,cell inside 3T3 
cells (Fig. 11a) increased linearly with the applied (extracellular) labeling concentration of 
contrast agent (from 0.1 μM to 1.0 μM). The apparent “intracellular” relaxation rates were 
plotted against the extracellularly applied concentration. Nevertheless, the measured 
intracellular relaxation rate increased significantly after loading with 0.5 µM and 1 µM anti-
dsred CA. Contrast enhancement in T1-weighted MR images of cells was also observable at 
these low concentrations; an example is shown for a single experiment in Figure 11b. The 
results of the MR measurements are summarized in Table 3, also illustrating that already at 
0.5 µM applied concentration, a statistically significant increase of the intracellular relaxation 
rate R1,cell and thus a contrast enhancement was detectable. 
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Figure 11. Contrast enhancement properties of anti-dsred CA in 3T3 cells. (a) 
Relaxation rate R1,cell and (b) T1 weighted MR images of 3T3 cells after loading with 
anti-dsred CA. After treated with anti-dsred CA for 18 h, cells were trypsinized, centrifuged and re-
suspended in 1.5 mL Eppendorf tubes at 1 x 107 cells/500 µL in complete DMEM for MR studies. The measured 
relaxation rates were plotted vs. the extracellularly applied labeling concentration. The sagittal images were 
obtained with a field of view 14 x 6.9 cm2, matrix 256 x 256, slice thickness 2 mm, SW 100 kHz, TE 9.2 ms, TR 
1500 ms, 26 averages for T1 weighted images. 
Labeling concentration [µM] 0.5 1.0 2.5 
R1,cell [% of control] 112 ± 0.5** 132 ± 3.7** 144 ± 1.9** 
n 3 3 2 
 
Table 3. Intracellular relaxation rates R1,cell in 3T3 cells after loading with anti-dsred 
CA for 18 h. Values are means ± SEM; **: p<0.01 statistically different as compared to control (100 ± 0.6 %), 
ANOVA with Dunnett´s post test; n: number of experiments, each with two replicates. 
The results from both fluorescence and MR studies directed towards further studies on 
transgenic cell lines to prove the specific accumulation by targeting the mRNA. 
2.3.6 Cellular uptake and internalization studies in target-containing cells 
CPPs have been used for the delivery of a vast variety of biomolecules. The ability of D-
Tat(57-49) to transport our covalently-conjugated PNAs along with the imaging moieties was 
next investigated in target containing cells. Murine fibrosarcoma cells transfected with the 
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DsRed2 gene (96), referred to as DsRed cells, and their parent cell line CCL-11 were used for 
internalization assessment by fluorescence spectroscopy and microscopy. 
The anti-sense CA as well as the non-sense CA labeled DsRed cells very efficiently (Fig. 
12). Both CAs showed a concentration-dependent transfer into cells up to a labeling 
concentration of 5 µM. Saturation in internalization was observed at labeling concentrations 
>2.5 µM and a further dose increase was accompanied by increased toxicity but only a 
marginal improvement in cellular delivery. Thus, for subsequent studies a labeling 
concentration of 2.5 µM of the PNA-containing CA was used. A comparable uptake profile 
for both CAs was observed in the non-target containing CCL-11 cells (data not shown). 
 
Figure 12. Internalization of anti-dsred and non-sense CA in DsRed mouse 
fibrosarcoma cells. Fluorescence spectroscopy was performed on cells incubated with 2.5 µM of either 
anti-dsred or non-sense CA for 18 h. External fluorescence was quenched with trypan blue and subsequent 
washes with HBSS; Values are means ± SEM, n=3 with six replicates each. 
Additionally, observations of DsRed and CCL-11 cells by fluorescence microscopy 
revealed similar uptake and distribution for both the PNA-containing CAs (Fig. 13). These 
agents were distributed in the peri-nuclear area as bright punctuate dots in both cell lines. 
This indicates that despite the difference in the base composition of the two PNA sequences, 
both anti-sense and non-sense CA have similar cellular internalization efficacy and 
properties. 
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Figure 13. Intracellular distribution of anti-dsred and non-sense CA in DsRed and 
CCL-11 mouse fibrosarcoma cells. Fluorescence microscopy was performed on cells incubated with 
2.5 µM of either anti-dsred or non-sense CA for 18 h. External fluorescence was quenched with trypan blue and 
subsequent washes with HBSS. The bar represents 20µm. 
2.3.7 Enhancement of MR contrast in target-containing cells 
The possibility to utilize these PNA-containing conjugates as MR contrast-enhancing 
agents in target-containing cells was assessed. Cells producing target mRNA as well as non-
target expressing cells were labeled with 2.5 µM of either the anti-sense CA or non-sense 
CA. 
In agreement with our earlier observations, both conjugates showed significant contrast 
enhancement in cells (104). The T1 relaxation times in DsRed cells were substantially altered 
by the non-sense as well as anti-sense CA at concentrations as low as 2.5 μM (Fig. 14). 
Remarkably, this labeling concentration was 20-1000 times lower than the amount of CPP 
linked Gd-based chelators used for delivery into cells (20, 64, 66, 68, 105). T1-weighted 
37 
 Chapter 2: mRNA targeted contrast agents 
images of CCL-11 cells showed similar contrast changes at these low concentrations. The 
extended incubation times used for CA delivery into cells could be the reason why this low 
concentration is sufficient for significant contrast enhancement. 
 
Figure 14. T1-weighted MR images of DsRed cells after loading with 2.5 µM of anti-
dsred and non-sense CA for 18 h. After treatment with anti-dsred CA for 18 h, cells were trypsinized, 
centrifuged and re-suspended in 1.5ml Eppendorf tubes at 2 x 107 cells/500 µl in complete medium for MR 
studies. Control: cells incubated with culture medium without CA. 
The target-containing DsRed cells demonstrated a slightly increased uptake of the anti-
sense CA compared to the parent CCL-11 cells (Fig. 15). However, no specific accumulation 
of the anti-sense CA in comparison to the non-sense CA could be detected in DsRed cells. A 
decreased rotational correlation time and thus a greater τr effect was expected upon binding of 
anti-sense CA with DsRed2 mRNA (106). However, no such effect was observed even in the 
target-containing cells. These findings suggest that although the CPP-PNA CAs efficiently 
permeate cells, their interaction with the target mRNA appears limited. 
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Figure 15. Cellular relaxation rate R1,cell in DsRed and CCL-11 cells after labeling 
with anti-dsred or non-sense CA. After treatment with DsRed CA for 18 h, cells were trypsinized, 
centrifuged and re-suspended in 1.5ml Eppendorf tubes at 2 x 107 cells/500 µl in complete medium for MR 
studies. The measured relaxation rates were plotted vs. the applied extracellular labeling concentration. Control: 
cells incubated with culture medium without CA. Values are means ± SEM, n=3 with two replicates each. *: 
p<0.05, **: p<0.01 statistically significantly different to control; a: p<0.05 statistically significantly different 
between contrast agents, ANOVA with Tukey’s post test. 
2.3.8 Fluorescence microscopy studies 
High resolution microscopy was performed to further elucidate the intracellular 
distribution of the FITC-containing CPP-PNA conjugates. DsRed cells were cultured in 
channel slides and labeled with anti-sense CA. After removal of surface-bound fluorescence 
by trypan blue and nuclear staining with Hoechst, cells were examined under the microscope. 
3D images were reconstructed from the 2D slice images thus obtained (107). 
Examination of DsRed cells labeled with anti-sense CA in 3D clearly revealed 
encapsulation of green fluorescent CA in intracellular vesicles around the nucleus (Fig. 16). 
Although the target mRNA cannot be visualized by microscopy, it is expected to be 
distributed mainly throughout the cytosol, as is the case with the red fluorescent DsRed2 
protein itself. On the other hand, the CA seemed to be entering cells by endocytosis and 
subsequently entrapped in endosomal/lysosomal vesicles with little or no release into the 
cytosol. 
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Figure 16. Endosomal localization of anti-dsred CA in DsRed cells. Cells were incubated 
with anti-dsred CA and cell nuclei were counterstained by Hoechst 33342. External fluorescence was quenched 
by trypan blue and subsequently washed with HBSS; DsRed CA: green (FITC fluorescence); nuclei: blue 
(Hoechst 33342). The 3D image was rendered from obtained 2D slices. A single unit of the grid represents 13.3 
µm. 
An interesting observation was that subsequent to quenching with trypan blue no traces of 
green fluorescence binding to the cellular membrane were noticed. Trypan blue interacts with 
the aromatic groups on FITC and therefore the fluorophore in the extracellular environment 
as well as the FITC in cells with compromised cell membrane integrity becomes quenched. 
This justifies the use of this stain to efficiently eliminate extracellular and membrane-bound 
fluorescence. Microscopic examination also indicates that, because of the quenching step in 
our washing protocol, only the internalized probe signal is quantified by fluorescence 
spectroscopy. 
2.3.9 Biodistribution properties 
Coupling of PNA with Gd-DOTA-CPP(FITC) more than doubles the size of the 
conjugate. Thus, it was important to investigate the mobility of this large molecule in vivo. 
Fluorescence studies performed 20 mins after i.v. injection showed that within minutes the 
compound entered various organs via the bloodstream, and was by no means limited to the 
injection site (Table 4). 
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Tissue 
Fluorescence 
Intensity 
Liver +++ 
Urinary 
bladder +++ 
Kidney ++ 
Spleen ++ 
Lungs + 
Heart +/- 
Brain - 
Blood - 
 
Table 4. Biodistribution of the anti-sense CA in various tissues represented 
qualitatively. Tissues from C57/BL6 mice were extracted 20 min after CA administration and tissue slices 
were assessed for anti-sense CA-related green fluorescence. Tissues from animals injected with saline alone 
served as control. 
The fluorescence observed in the liver and bladder was very high and the exposure time 
for fluorescence images was reduced almost 3.5 times in comparison to the rest of the tissues 
(Fig. 17). The lipophilic nature of the PNA-containing CA explains the affinity of the 
conjugate for liver tissues. Kidney and spleen were moderately labeled whereas heart and 
lungs were only faintly fluorescent. Absolutely no fluorescence of FITC from the CA was 
detected in the brain, thus indicating a lack of penetration of the blood brain barrier. Although 
these biodistribution studies are preliminary, they clearly indicate that the bulky PNA-
containing anti-sense CA spontaneously disperses in the organism after injection and also 
rapidly enters the excretory system. 
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Figure 17. Distribution of anti-dsred CA in different tissues after in vivo labeling. 
Tissues were extracted 20 min after intravenous administration of anti-dsred CA to C57/BL6 mice. Fluorescence 
and bright field images of the tissues were obtained. For fluorescence images of liver an exposure time of 175 ms 
was used while for all other tissues it was adjusted to 600 ms. The bar represents 160 µm. 
2.4 Discussion 
Among the increasing number of transduction peptides that are being characterized, HIV-
1 Tat and polyarginines represent two of the particularly well-studied. Over the years more 
efficient sequences have been derived by modifications of Tat CPP (56, 101). Furthermore, a 
higher toxicity of polyarginines in comparison to Tat has been suggested (108). Therefore, 
we started with the evaluation of the efficiency of three HIV-1 Tat derivatives to translocate 
MR CAs together with FITC into cells. Thus far, there are only a few publications about the 
use of HIV-1 Tat to transport CAs for MRI (64, 65). Large amounts of CA need to be 
transported into cells to obtain maximum MR contrast enhancement because of the low 
sensitivity of MRI. Therefore, we chose long incubation times and labeling protocols 
comprising of incubation in the presence of serum supplemented medium and an incubation 
temperature of 37°C. A routine laboratory embryonic mouse fibroblasts cell line NIH 3T3 
was selected for comparison of uptake efficiency. 
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Our results accounted highest uptake accompanied with high cell death for Orn-D-Tatinv 
CA, thus limiting its further exploitation. Although D-Tat(57-49) has been accounted for more 
efficient delivery of variety of cargos (102), in our hands we obtained a comparable delivery 
with the L-Tat CA. This difference could be attributed to the influence of the Gd-loaded 
chelate on the molecular charge or three-dimensional conformation of the conjugate. On the 
other hand, it is well-established that D-isomers of amino acids are resistant to enzymatic 
cleavage and remain longer in the circulation (102). Thus, D-Tat(57-49) was chosen as the CPP 
for experiments on further coupling of PNA sequences together with Gd-DOTA and FITC to 
obtain bimodal targeting agents. 
Based on this evaluation, our goal was to design a multi-modal probe by the use of a 
facile building block approach. The blocks could easily be altered according to the target 
requirement without significant modification in the synthetic scheme. The final molecule 
designed consisted of MR and optical imaging parts linked to a PNA essential for targeting 
and a CPP for intracellular delivery. Antisense PNA conjugated with different cell 
penetrating peptides (such as PTD-4 or poly-lysine) and radiometal complexes (such as 111In, 
90Y or 64Cu) has been reported as nuclear imaging probes (PET and SPECT) (81, 109). But 
the utilization of such conjugates as contrast agents for MR imaging is very limited, probably 
because the accumulation of the PNA imaging probes in the targeting cells could barely reach 
a detectable level. Heckl et al. developed a MR contrast agent combining a Gd3+-complex 
with antisense PNA targeting the c-myc mRNA and Antennapedia peptide (68). Using this 
contrast agent, an increase in MR signal intensity and prolonged retention in tumor cells 
highly expressing this gene was observed in vitro and in vivo. 
The cell-free in vitro binding studies clearly depicted a considerable specificity in the 
interaction between the anti-sense PNA and the complementary ODN sequence. In contrast, 
the non-sense CA showed no binding to the target sequence. Attempts were made to establish 
a similar specificity of the intracellularly taken up CAs using fluorescence in situ 
hybridization (FISH). To our surprise, no detectable fluorescence signal was identified in 
cells labeled with anti-dsred CA. 
Our anti-dsred and non-sense CAs are very efficiently taken up by target containing 
(DsRed) as well as non-target containing (3T3, CCL-11) cell. Thus, the feasibility of using 
D-Tat(57-49) as a transport vector for large-sized cargos has again been demonstrated. In fact, 
efficiency similar to that of the D-Tatinv CA was observed when an almost 10 times lower 
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labeling concentration of the PNA-containing CAs was used. Despite the large increase in 
molecular weight, the PNAs increase the hydrophobic nature of the cargo. We hypothesize 
that the CPP-PNA CAs might interact better with the cell membrane and hence enhance 
uptake. Also, the applied concentration of contrast agent (0.5 mM) in Heckl’s study (68) was 
1000x higher compared to the lowest concentration of anti-dsred CA in our experiments 
showing a significant increase in relaxation R1,cell within the cells. The difference is likely 
attributable to the different cell penetrating peptides and the Gd3+ moiety used. Thus, the 
synthesized anti-dsred CA has an excellent potential to be used as targeted contrast agent for 
MR imaging in cells expressing the DsRed2 gene. Although, the high hydrophobicity of the 
conjugates containing PNA reduced their solubility in water, therefore, the PNA-containing 
conjugates could be used only at low micro-molar concentrations for labeling cells. 
The target containing cells labeled with anti-dsred and non-sense CAs were subjected to 
MR studies as well as high resolution microscopy. No considerable interaction between the 
targeting PNA with mRNA was observed by any examination. MR studies did depict a 
significant increase in cellular relaxation rates of DsRed cells labeled with anti-dsred CA 
compared to cells without any target. However, the non-sense CA also showed a significant 
contrast enhancement in comparison to the control cells. This could mainly be due to the 
endosomal entrapment of most of the targeting CA in spite of having entered into cells, thus 
segregating and hindering binding with target mRNA. As more information is obtained about 
the mechanism of cellular delivery by CPPs, it is becoming evident, as also reported by other 
groups, that endocytosis is the main route of trans-membrane movement (110-112). However, 
there is a lack of definitive evidence on the maintenance of functionality of the CPP-
associated cargo once it is conveyed into cells. Some studies indicate successful PNA 
interaction with the target after being delivered by membrane-transducing peptides (113-
115). Other studies indicate limited PNA binding with the target due to entrapment of PNA 
conjugates in endosomes (116, 117). 
Another possible reason could be the non-specific interaction of the non-sense sequence 
in the rich pool of biomolecules inside the cell. These non-specific interactions could be the 
cause of cellular relaxation rate enhancement of both the CAs in cells deficient of target 
sequence. Thus, other non-sense sequences need to be tested to verify this.  
The small amount anti-dsred CA that might be reaching the target could be out of the 
detection limit of MR. Thus, more methods like PET could be used for improving the 
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sensitivity. This could be easily performed by replacement of Gd with a radiometal and 
testing with target containing or deficient cells. 
For future application, additional modifications are needed for developing CPPs with 
better penetration properties, especially directed into the cytoplasmic compartment. 
Endosomal localization of the probes is expected to be a hindrance to specific binding to the 
targeted mRNA located in the cytoplasm. This is, in fact, a general problem facing many, if 
not all, MR contrast agents synthesized to date for the purpose of intracellular reporting. 
Endosomal uptake, however, is likely to represent only “inefficiency”, as endosomes retain a 
majority of the CA while only a minute part does ultimately show up in the cytoplasm. 
Leakage from endosomes or a direct uptake into the cytoplasm is a possibility and towards 
achieving this goal we are currently working on developing novel CPPs. Release from 
endosomes depending on their acidification is reported for some fluorescein coupled CPP 
(57) but is also cell type dependent. In this study Fischer et al. depicted an enhanced 
degradation of the CPP followed by a rapid exit of its fragments from the cytosol for the 
HIV-Tat peptide (consisting of the native L-form aminoacids) coupled to fluorescein 
resulting in a low cytosolic fluorescence. Since for our study, we used the D-form of the 
amino acids for synthesizing CPPs, an increase of their stability towards proteases would 
prevent the cytosolic release of our CA. Thus, it will be interesting to look for novel CPPs 
that possess high delivery efficiency with the native form of amino acids and also evade the 
entrapment into the endosomes. 
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Chapter 3: Development of a novel cysteine-rich Cytosolic 
Localizing Peptide CyLoP-1 and understanding its delivery into 
the cytosol 
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3.1 Introduction 
Cell delivery vectors (CDVs) possess the innate ability to permeate through biological 
membranes and also efficiently translocate meagerly penetrating macromolecules inside cells 
(118). Often referred as cell penetrating peptides (CPPs) or peptide transduction domains 
(PTDs), CDVs are generally short cationic peptides that could either be derived from natural 
proteins like HIV1-Tat (119, 120) and penetratin (90, 121) or have a synthetic origin like 
polyarginine (51) and transportan (52). These peptides have been reported to deliver cargoes 
ranging from small molecules like fluorophores to large sized plasmid DNA and liposomes 
(122, 123). However, the activity for the imported cargo was maintained in some cases (49, 
103, 124, 125) while many accounted failures (62, 116, 126-130). The lack of functionality 
was reasoned by the mechanism of internalization of CDVs which is not only complex but 
also extensively debated. Interestingly, most of the recent studies indicated that majority of 
CDVs entered the cells by one or the other endocytotic pathways (58, 110, 112, 131), thus, 
limiting the target molecule into the endosomal compartment. This necessitates the release of 
endocytosed material, before lysosomal enzymes and low pH degrade them. 
An alteration of intracellular distribution pattern as a result of the induction of alternative 
non-endocytic routes of uptake was observed by Brock and coworkers upon application of 
high concentrations of HIV1-Tat and nona-arginine (58). More often liberation of cargo has 
been investigated using the combination of CDVs with lysosomotropic agents like 
chloroquine (132, 133), addition of calcium (134) or introduction of influenza virus HA2 
hemagglutinin subunit (132, 135). Futaki et al. also reported the use of pyrenebutyrate as a 
counteranion with poly-arginines for rapid and direct cytosolic delivery (136, 137). 
Nevertheless, most of these chemicals effectively transport into the cytosol only in the 
absence of serum which is a very non-natural condition for in vivo applications. In addition, 
these chemicals are effective at concentrations that either induce toxicity or cause stress on 
cells, thus, initiating several other degenerative pathways (138, 139). 
An ideal approach for cellular delivery would assist in enhanced uptake of the molecule 
of interest either by direct permeation of the cellular membrane or be followed by discharge 
and localization in intracellular compartment of interest. In nature, there are quite a few 
examples of peptides and proteins from bacterial or plant toxins and venoms from snakes, 
spiders, jellyfish and sting rays (140-142). They induce their detrimental effects by directly 
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overcoming the barriers of plasma membrane and/or deliver their active domain inside cells. 
Based on the structural properties of these toxins, new classes of CPPs having the optimum 
delivery, localization and efficiency are being engineered (143, 144). 
The cell-penetrating properties of crotamine, a toxin from the venom of a South American 
rattlesnake, were recently reported by Kerkis et al. (145). The unique feature of this 42 amino 
acid polypeptide is its ability to mark actively proliferating cells and to bind chromosomes 
and centrioles. We selected one of the proposed sequences (Crot27-39) that could be apparently 
guiding the nuclear localization of this polypeptide. Herein we present an extensive structure 
and functionality evaluation that was performed on the sequence involving the synthesis of 
different peptides using systematic substitution and/or deletion of amino acid residues as well 
as epimerizations (Table 5) and testing for their uptake efficiency. This investigation lead to 
the identification of a novel peptide, CyLoP-1, distinguishingly localizing into the cytosol 
(146). This short cationic peptide with three cysteine residues offers abundant possibility for 
exploitation as a delivery tool for intracellular targeting. 
A further detailed characterization of the intracellular delivery ability of CyLoP-1 was 
carried out. The purpose of this study was the characterization of the biochemical properties 
and intracellular delivery of CyLoP-1 to achieve a better understanding of the unique uptake 
behavior of this peptide. The factors responsible for the distribution within the cytoplasm 
were examined by observing serum stability, uptake under different conditions and in various 
cell types as well as investigating the effect of CyLoP-1 on the cellular metabolism. 
3.2 Materials and Methods 
3.2.1 Materials 
All chemicals for synthesis were purchased at purest HPLC and peptide synthesis grade 
from commercial sources. 3T3 embryonic mouse fibroblasts and C6 rat glioma cells were 
obtained from DSMZ, Germany, PANC-1 human carcinoma cells were procured from 
ATCC, USA, N18 mouse neuroblastoma cells were a kind gift of Prof. Bernd Hamprecht 
(University of Tuebingen, Germany) and SHIN3 human ovarian cancer cell line was kindly 
gifted by Prof. Silvio Aime (University of Torino, Italy). Dulbecco’s Modified Eagle’s 
Medium (DMEM), Iscove's Modified Dulbecco's Medium (IMDM), Hank’s buffered saline 
(HBSS), phosphate buffered saline (PBS), fetal bovine serum (FBS), granulocyte 
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macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) were obtained from 
Biochrom AG (Germany). Bisbenzimid 33342 (Hoechst 33342), 2,3-bis(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt (XTT), monobrombimane (MBBr), 
N-ethylmaleimide (NEM), propidium iodide (PI), Nonidet P-40, trypan blue were procured 
from Sigma Aldrich (Germany). 
3.2.2 Peptide synthesis 
N-terminally labeled fluorescein isothiocyanate conjugated peptides were synthesized 
using an automated peptide synthesizer (peptides&elephants, Germany) by continuous solid 
phase Fmoc/tBu chemistry. All samples were purified by semi-preparative RP-HPLC (Varian 
PrepStar Instrument, Australia) equipped with PrepStar SD-1 pump heads. Mass 
spectrometry (ESI-MS) was used for further characterization. The purified products were 
lyophilized, divided into aliquots and stored at -20°C till used. 
3.2.3 Cell Culture 
3T3 embryonic mouse fibroblasts, SHIN 3 human ovarian cancer cells, C6 rat glioma 
cells and PANC-1 human pancreatic carcinoma cells were cultured as monolayers in DMEM 
supplemented with 10% FBS, 4 mM L-glutamine, 100 µg/ml streptomycin and 100 U/ml 
penicillin at 37°C with 10% CO2. Cells were trypsinized and passaged every second to third 
day. 
N18 mouse neuroblastoma cells were cultured in an antibiotic free DMEM supplemented 
with 10% FBS and 4 mM L-glutamine at 37°C with 5% CO2. Cells were sub-cultivated by 
trypsinization two times a week. In order to induce differentiation of neuroblastomas, slow 
step-wise serum deprivation was used till FBS content was reduced to 1.25% in medium. 
Hematopoietic stem cells (HSCs) were isolated from C57/BL6 mouse bone marrow and 
cultured in IMDM supplemented with 10% FBS, 1% GM-CSF, 1% IL-4 and antibiotics. The 
cells were cultured for 7 days with change of medium on day 3 and day 5. On the 7th day, 
cells were scraped from plates and re-seeded in µ-dish (Ibidi, Germany) for another 24 h. 
3.2.4 Evaluation of peptide uptake by fluorescence spectroscopy 
The uptake efficiency was assessed using 3T3 fibroblasts grown to 70-80% confluency in 
96well microplates. The cells were incubated with different peptides at identical 
concentration or single peptide over a range of concentrations in supplemented DMEM for 
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additional 18 h at 37°C with 10% CO2. In order to estimate the cell number, the cellular 
nuclei were stained by incubating cells with Hoechst 33342 for another 30 min. All traces of 
peptide-related extracellular fluorescence were quenched by incubating with cold trypan blue 
in PBS for 3 min followed by repeated washes with HBSS (100, 147). In a multiplate reader 
(BMG Labtech, Germany), the cell-related FITC fluorescence (Ex 485nm/Em 530nm) and 
cell number (Hoechst fluorescence, Ex 346nm/ Em 460nm) were measured. Intracellular 
FITC fluorescence intensity was corrected for cell number and the result, multiplied by 1000, 
expressed as “corrected fluorescence units” (corr. f.u.). 
Time course studies were made by maintaining the labeling concentration of peptides 
constant and incubating cells for various periods of time. 
To study the effect of low temperature on cellular uptake and distribution, 3T3 cells were 
pre-chilled for 30 min at 4ºC. These cells were then incubated with FITC labeled peptide for 
additional 4h at 4ºC. 
Experiments were run at least three times for each peptide with six replicates. Statistical 
analysis was performed by Student´s t-test or ANOVA with Bonferroni’s post test for 
multiple comparisons. P values < 0.05 were considered significant. 
3.2.5 Analysis of cellular localization by live cell imaging 
The cells from the 96well plates for spectroscopy imaged without fixation using a Zeiss 
Axiovert 200 M microscope (Zeiss, Germany) with a LD Plan NeoFluor 40X objective. 
Imaging of N18 neuroblastoma was performed in single channel slides (Ibidi, Germany) and 
stem cells isolated from mouse bone marrow in µ-dish (Ibidi, Germany). The imaging 
conditions were kept constant for the observation of different samples. Cellular localization 
and distribution of the peptide was observed by irradiating with blue light (470/40 nm) and 
observing at 525/50 nm. The bright punctate and encapsulated appearing FITC fluorescence 
was categorized as vesicular uptake while diffused fluorescence appeared to be distributed in 
the entire cell. Manual observations of at least three independent experiments were compiled 
to conclude if the peptide shows diffused, vesicular or both types of uptake. Apart from FITC 
fluorescence, the nuclear labeling by Hoechst 33342 was observed at 460/50 nm and trypan 
blue fluorescence viewed at 645/75 nm. Also phase contrast images of the same area were 
made to observe if the cells maintained their normal morphology in the presence of peptides. 
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The uptake of peptide was also assessed by labeling different cells (SHIN3, N18 and 
HSCs) for 18 h at a concentration of 2.5 µM followed by washing and microscopic 
observation as explained before. 
3.2.6 Cytotoxicity assay 
Toxicity of the peptides was investigated by a XTT based colorimetric cellular viability 
assay. 3T3 cells were grown to subconfluency in 96-well plates. The cells were incubated 
with various concentrations of peptides for 4 or 18 h under normal growth conditions and cell 
viability was subsequently measured by the XTT assay. After treatment, cells were incubated 
for 30 min with a freshly prepared solution of XTT (0.25 mM) with PMS (0.5 µM). The 
absorption of the water-soluble colored formazan derivative formed by the conversion of 
XTT was measured at 450 nm with reference wavelength at 690 nm in the multiplate reader. 
The DNA content of the cells was also quantified by Hoechst labeling of the same cells and a 
correlation to the cell number was made measuring the fluorescence at Ex 346nm/ Em 
460nm. 
3.2.7 Propidium iodide membrane integrity assay 
3T3 cells were seeded 24 h before treatment in 96well plates at 6×103 cells/well. Cells 
were treated for different durations by incubating with medium containing 5 or 2.5 μM of 
peptide conjugates (CyLoP-1 and penetratin). After incubation, the peptide-containing 
solution was removed and PI in HBSS was added to cells. After another 20 min the 
fluorescence of this labeling was measured at Ex 530 nm/Em 645 nm. Also microscopic 
observations were made to look for cells with compromised plasma membranes labeled with 
PI. As PI stains only DNA of non-vital cells, the surfactant Nonidet P-40 was added 
afterwards for 20 min to lyse all vital cells. Their fluorescence was measured again to 
determine the total cell number per well. 
3.2.8 Analyzing interaction of peptide with glutathione 
The glutathione content of cells was measured by a slightly modified assay using MBBr 
as described elsewhere (148). Briefly, 3T3 cells were grown in 96well plates for 24 h 
followed by treatment with various concentrations of peptide conjugates (CyLoP-1 and 
penetratin) for 1, 4 or 18 h. Subsequent to incubation and removal of treatment medium, cells 
were washed with HBSS. Then, MBBr in HBSS was added to the plate and after 30 min 
incubation in dark the fluorescence intensity of MBBr-glutathione was measured at an 
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excitation wavelength (Ex) of 360 nm and an emission wavelength (Em) of 460 nm. MBBr 
readings were corrected by total cell number values determined by PI staining. Background 
staining of the protein sulfhydryl groups was determined in cultures after depletion of 
glutathione with NEM. 
3.2.9 Serum stability 
FITC labeled CyLoP-1 and L- and D-form of Tat and octaarginine were incubated in 
serum-free or serum-containing medium for 30 min. The peptides were then analyzed by a 
nondenaturing gel electrophoresis. The bands were imaged for FITC fluorescence. Also 
coomassie brilliant blue staining of the peptides in the gel was conducted. 
3.3 Results 
3.3.1 Generation of a more effective CPP by Structure-Activity-Relationship 
studies 
The starting sequence tridecapeptide Crot27-39 (peptide 1, KMDCRWRWKCCKK) 
included three cysteine residues, tryptophans, aspartic acid, methionine along with six basic 
amino acids (arginine and lysine). The positively charged amino acids were kept unaltered 
considering the requirement of cationic residues for membrane adherence (51). Cysteine 
residues in peptides are known to modify the biological activity of the peptide by their ability 
to form intra- and intermolecular bridges and hence promote oligomerization (149). However 
cysteine, methionine and tryptophan moieties in peptides also cause side reactions such as 
racemization, oxidation and alkylation (150-153). Therefore, studies were carried out to 
evaluate the functional significance of these residues. SAR studies were performed to achieve 
a sequence optimized for cell penetrating properties, as well as production and shelf life. The 
importance of each of the amino acids of Crot27-39 for the cellular internalization was assessed 
leading to the optimal peptide, CyLoP-1, with unique properties (Table 5). 
Table 5. Sequences of 38 synthesized peptides, the calculated and observed 
molecular mass (M+H)+, intracellular fluorescence intensity and percentage of 
CyLoP-1 of the conjugates. (K(FITC) was coupled to all peptides at the N-terminus), and intracellular 
fluorescence intensity (corr. f.u.) values in NIH 3T3 cells after a labeling period of 18h at 2.5 µM. D-amino acids 
are represented in lower case. In some cases molecular ion is calculated from the divalent ion. 
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Peptide 
 
Sequence 
Molecular Weight Intracellular fluorescence intensity [corr. f.u.] % of 
CyLoP-1 Expected 
(M+H)+ 
Observed 
(M+H)+ Mean SEM 
       
1 KMDCRWRWKCCKK Crot27-39 2288.7 2288.6 3176 271 78 
2 MDCRWRWKCCKK 2160.5 2162.0 3344 374 83 
3 DCRWRWKCCKK 2029.3 2029.9 1909 272 47 
4 CRWRWKCCKK 
(CyLoP-1) 
1914.3 1914.9 4050 322 100 
5 RWRWKCCKK 1809.1 1811.3 1511 256 37 
6 KMDCRWRWKCKK 2185.6 2186.4 1516 181 79 
7 KMDCRWRWKKK 2082.4 2084.7 1202 218 30 
8 KMDRWRWKKK 1979.3 1979.6 100 50 2 
9 KDCRWRWKCCKK 2157.5 2159.2 1043 137 26 
10 KCRWRWKCCKK 2042.4 2043.0 1583 246 39 
11 KRWRWKCCKK 1939.3 1940.8 1226 120 30 
12 MDCRWRWKXCKK 2142.5 2142.0 1937 335 48 
13 DCRWRWKXCKK 2011.3 2013.0 1741 427 43 
14 DCRWRWKCXKK 2011.3 2011.6 943 313 23 
15 CRWRWKXCKK 1896.2 1897.0 2044 408 50 
16 CRWRWKCXKK 1896.2 1896.6 1347 171 33 
17 RWRWKXCKK 1793.1 1793.1 1211 529 30 
18 MDCRWRWKXXKK 2124.5 2124.8 1256 187 31 
19 DCRWRWKXXKK 1993.3 1993.8 872 554 22 
20 CRWRWKXXKK 1878.2 1880.0 1390 199 34 
21 RWRWKXXKK 1775.0 1776.2 405 109 10 
22 CRWRWKCSKK 1898.2 1899.0 2172 597 54 
23 SRWRWKCCKK 1898.2 1898.6 1867 367 46 
24 SRWRWKCSKK 1882.1 1881.9 572 94 14 
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Peptide 
 
Sequence 
Molecular Weight Intracellular fluorescence intensity [corr. f.u.] % of 
CyLoP-1 Expected 
(M+H)+ 
Observed 
(M+H)+ Mean SEM 
       
25 SRWRWKSCKK 1882.1 1882.4 475 77 12 
26 CRWRWKSSKK 1882.1 1882.0 415 109 10 
27 SRWRWKSSKK 1866.1 1866.0 193 89 5 
28 CRFRWKCCKK 1875.2 1875.0 2656 320 66 
29 CRWRFKCCKK 1875.2 1875.8 2476 382 61 
30 CRFRFKCCKK 1836.2 1836.8 2569 197 63 
31 crwrwkcckk 1914.3 1914.8 2109 503 52 
32 KCCKWRWRCK 1914.3 1914.9 1713 148 42 
33 kcckwrwrck 1914.3 1914.9 1449 295 36 
34 CrWRWKCCKK 1914.3 1914.1 1529 163 38 
35 CRwRWKCCKK 1914.3 1913.9 1229 40 30 
36 CRWrWKCCKK 1914.3 1915.0 1304 345 32 
37 CRWRwKCCKK 1914.3 1914.0 1412 456 35 
38 CrwrwKCCKK 1914.3 1915.0 1488 360 37 
 
3.3.2 CyLoP-1 shows efficient cellular internalization 
Cellular uptake efficiency of CyLoP-1 conjugated to lysine-FITC was investigated by 
fluorescence spectroscopy. A concentration of 2.5 μM was chosen for labeling 3T3 cells as at 
this concentration the peptide had good solubility in supplemented culture medium and 
demonstrated no cytotoxicity. A time course of uptake was evaluated and compared with 
standard CPPs namely penetratin and d-Tat (HIV-1 Tat(47-59)) sequence with d-form of amino 
acids) also coupled to lysine-FITC. CyLoP-1 exhibited a time dependent increase of uptake 
even after 24 h of treatment (Fig. 18). Although, both penetratin and d-Tat also labeled cells 
very rapidly, they displayed a constant increase in the first 12 h which was followed by a 
decrease after longer incubation. 
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Figure 18. Time dependent uptake of CyLoP-1 in 3T3 cells. Cells were incubated for various 
time points with 2.5 μM of the different peptides in complete medium at 37 °C. After nuclear staining and trypan 
blue quenching A) fluorescence spectroscopy and B) microscopy were performed to assess the internalization. 
Spectroscopy values are mean ± SEM, n = 3-6 with six replicates each. The bar represents 20 µm. 
On increased labeling doses, a concentration dependent increase in uptake efficiency was 
observed (Fig. 19 A). The maximum applicable amount was 5 µM as at higher concentrations 
a precipitation was observed (Fig. 19 B). CyLoP-1 was soluble up to milli-molar 
concentrations in pure water but in supplemented medium its solubility was limited. 
Nevertheless, these low micro-molar concentrations are sufficient for long term labeling of 
cells. 
 
Figure 19. Concentration dependent uptake of CyLoP-1 in 3T3 cells. Cells were 
incubated for 18 h with 2.5 μM of CyLoP-1 in complete medium at 37 °C. After nuclear staining and trypan blue 
quenching A) fluorescence spectroscopy and B) microscopy were performed to assess the uptake. Spectroscopy 
values are mean ± SEM, n = 3 with six replicates each. The bar represents 20 µm. 
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To avoid any over-estimation of uptake efficiency by surface-bound extracellular 
fluorescence, a quenching step with trypan blue was incorporated (100, 147). Cells treated 
with CyLoP-1 up to 5 µM of labeling concentration appeared to have normal morphology 
and density with almost no signs of membrane permeation by trypan blue. In addition, the 
long term detrimental effects at different peptide concentrations and various time points was 
evaluated by XTT and Hoechst staining (Fig. 20). We observed that on measuring XTT, the 
high labeling dose of 9 µM also did not indicate any toxicity in 3T3 cells even when treated 
for long term. On the other hand, the evaluation of DNA content by Hoechst displayed about 
30% reduction in cell number at 9 µM while lower concentrations were non-toxic. When the 
results of both assays were combined to normalize XTT values by the number of cells 
(XTTcorr. = XTT/Hoe×1000), an increase by 50% was observed at the highest concentration. 
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Figure 20. Cytotoxicity induced after long term application of high concentrations of 
CyLoP-1 on 3T3 cells. Cells were incubated with different concentrations of the peptide in complete 
medium at 37 °C. After HBSS wash, XTT assay was performed followed by DNA content estimation with 
Hoechst. The values from these two assays were combined for correction of XTT for cell number and the result 
after multiplication by 1000 was represented as XTT corrected (XTT corr.), values are mean ± SEM, n = 3 with 
six replicates each. 
3.3.3 Serum is essential for the solubility of CyLoP-1 
With the aim of evaluating the effect of serum on uptake efficiency, internalization assays 
were performed in the absence of serum or in the presence of various serum concentrations. 
The complete removal of serum from medium resulted in up to 50% reduction in the uptake 
of CyLoP-1 (Fig. 21). 
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Figure 21. Effect of serum in incubation medium on uptake of CyLoP-1 in 3T3 cells. 
Cells were incubated for 4 h with 5 μM of CyLoP-1 in serum containing (serum +) or serum deficient (serum -) 
medium at 37 °C. After nuclear staining and trypan blue quenching, fluorescence spectroscopic evaluation of 
internalization was performed, values are mean ± SEM, n = 6. 
Microscopic observations depicted the formation of a precipitate in serum-free medium 
even at a concentration of 2.5 μM which disappeared on addition of 1.25% FBS to the 
medium for treatment. The precipitation limited the uptake of CyLoP-1 and FITC 
fluorescence was largely detected bound to the membrane (Fig. 22). The increase of serum 
content in medium directly correlated with a rise in cellular uptake and cytosolic distribution 
of fluorophore. 
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Figure 22. Presence of serum in incubation medium enhances the uptake and 
cytosolic localization of CyLoP-1 in 3T3 cells. Cells were incubated for 4 h with 5 μM of CyLoP-1 
in serum-containing (serum +) or serum-deficient (serum -) medium at 37 °C. After nuclear staining and trypan 
blue quenching fluorescence spectroscopic evaluation of internalization was performed, values are mean ± SEM, 
n = 6. The bar represents 20 μm. 
The stability of CyLoP-1 was tested in the presence of serum to ensure that the 
internalization of fluorophore resulted by assistance of complete peptide and not through any 
by-products formed by extracellular degradation. CyLoP-1 was dissolved in serum 
supplemented medium and incubated under culture conditions for 18 h. On running this 
peptide solution through a polyacrylamide gel followed by coommassie brilliant blue 
staining, a band corresponding to the intact peptide was detected (Fig. 23). Comparison was 
made with the same peptide incubated in serum-free medium. 
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Figure 23. Stability of CyLoP-1 in serum containing medium after long term 
incubation. CyLoP-1 was incubated in serum containing (lane 1) or serum-free (lane 2) medium for 18 h 
followed by a run on denaturing gel. Ultra-low molecular weight marker (lane 3) was run to verify the molecular 
weights of the bands. The stability of the peptide was verified by FITC fluorescence (a) and after coommassie 
blue staining (b). 
To corroborate these results, the cellular internalization of lysine and cysteine-lysine, both 
conjugated to FITC, was quantified after 18 h incubation. No traces of the fluorescence were 
found inside cells, thus confirming the inability of small conjugates to enter into cells (Fig. 
24). 
 
Figure 24. Possible fluorophore-linked degradation products of CyLoP-1 do not 
penetrate into cells. 3T3 cells were labeled with FITC linked lysine (Lys-FITC) and cysteine-lysine (Cys-
Lys-FITC) for 18 h with 2.5 μM of CyLoP-1 in serum containing medium at 37 °C. After nuclear staining and 
trypan blue quenching fluorescence microscopy was performed. The bar represents 20 μm. 
3.3.4 Cytosolic distribution of CyLoP-1 
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CyLoP-1 labeled cells were assessed for cellular distribution by fluorescence imaging of 
living cells. A particularly cytosolic localization along with some vesicular uptake 
distinguished CyLoP-1 from penetratin, d-Tat (Fig. 25). A faint diffuse green fluorescence 
was observed in the early hours of incubation while longer incubation times displayed bright 
diffuse cytosolic localization at 2.5 µM of labeling concentration. Moreover, this time could 
be shortened by application of higher peptide concentration. Fig. 25 A appropriately 
demonstrates the intense cytosolic and dotted vesicular distribution patterns of CyLoP-1 after 
4 h of treatment with 5 µM concentration in interphase 3T3 cells after synchronization of 
culture. For synchronization, fresh mitotic cells were collected by gently tapping loosely 
adhering dividing cells from the culture flask and transferring for further culture in a new 
flask. 
 
Figure 25. Intracellular distribution of various CPPs in 3T3 cells. A.) CyLoP-1 shows 
vesicular and diffuse cytosolic distribution on application of 5 µM concentration for 4 h in synchronized 3T3 cells 
(left), 3T3 cells in routine culture (top right) and on application of 2.5 µM for 18 h (bottom right). In comparison the 
standard CPPs, penetratin (left), d-Tat(59-47) (middle) and d-octaarginine (right) displayed mainly a vesicular 
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distribution when 20 µM of CPP was applied for 18h on 3T3 cells in culture. All labeling was performed in serum 
supplemented medium. Before microscopy, cells were stained with Hoechst 33342, quenched with trypan blue 
and extensively washed with HBSS. The bar represents 20 μm. 
The intracellular distribution of CyLoP-1 was evaluated at different temperatures to 
determine the energy dependence of uptake of this peptide. Interestingly, at low incubation 
temperature the diffused cytosolic fluorescence was maintained but a strongly reduced 
vesicular distribution was observed (Fig. 26). Fluorescence spectroscopic measurements 
showed a significant reduction in the amount of peptide delivered into cells. Nevertheless, a 
complete inhibition of uptake could not be detected at low temperature. 
 
Figure 26. Cytosloic distribution of CyLoP-1 is maintained at low labeling 
temperature. 3T3 cells were labeled with different concentrations of CyLoP-1 for 4 h at 37 °C or 4 °C. 
Subsequent to nuclear labeling and trypan blue quenching A.) fluorescence spectroscopy and B.) fluorescence 
microscopy were performed. The bar represents 20 μm. 
3.3.5 CyLoP-1 interacts with cellular membrane and integrity of membrane is 
maintained 
To facilitate the transfer of cargo into cells, delivery vectors need to circumvent the 
phospholipid bilayer. Experiments were performed to evaluate the interaction of CyLoP-1 
with the plasma membrane in the initial uptake phase. Pre-chilled 3T3 fibroblasts were 
incubated with 5 μM of CyLoP-1 at 4ºC for 2 h. After incubation, labeling peptide was 
removed from cells without the step of trypan blue quenching. The same cells were further 
incubated in fresh peptide-free supplemented medium at 37ºC for another 2 h. 
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Microscopic observations after the removal of CyLoP-1 from cells depicted membrane 
bound distribution of most of the fluorescence (Fig. 27) indicating the role of the membrane-
peptide interaction before internalization. Furthermore, this membrane-bound peptide 
permeated inside the cells on subsequent incubation at 37°C and displayed vesicular along 
with minor diffuse fluorescence. 
 
Figure 27. Interaction of CyLoP-1 with cellular membrane at 4 °C followed by 
internalization of bound peptide on further incubation at 37 °C. 3T3 cells were labeled with 5 
µM of CyLoP-1 for 2 h at 4 °C. Microscopy was performed after removal of peptide-containing solution and 
one HBSS wash. The same cells were further incubated at 37 °C in peptide-free medium for an additional 2 h. 
After rigorous washing, the cells were observed under the microscope. No trypan blue quenching was performed 
for this evaluation. The bar represents 20 μm. 
The integrity of the plasma membrane was checked by PI to rule out that the intracellular 
diffuse localization was due to disruption of the lipid bilayer. After treatment with 2.5 or 7.5 
μM of CyLoP-1 for different time points, 3T3 cells were labeled with PI solution. In parallel, 
penetratin was tested at same concentrations and time durations. PI enters cells with leaky 
membranes and labels their DNA. Both peptides displayed an absence of nuclear staining by 
PI when evaluated by spectroscopic measurements (data not shown) as well as by microscopy 
(Fig. 28). The leftmost panel displays PI labeling of a dead cell after treatment with 7.5 μM 
of CyLoP-1. Almost 98% of the cell population comprised of healthy cells after CyLoP-1 or 
penetratin labeling and did not exhibit permeation of PI stain into cells. 
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Figure 28. Integrity of the plasma membrane assessed by PI staining after 
incubation of cells with CyLoP-1 or penetratin. 3T3 cells were labeled with different 
concentrations of CyLoP-1 or penetratin for 18h. Microscopy was performed after removal of peptide-containing 
solution, one time HBSS wash and staining of cells with PI to evaluate membrane integrity. The bar represents 
20 μm. 
3.3.6 Effect of stereochemical modifications on uptake 
The CPP-based delivery approach is potentially hampered by the instability of the vector 
to endogenous peptidases (56). The possible solutions to this hurdle could be the use of the 
D-form instead of the naturally occurring L- amino acids, use of beta-peptides (154) or 
peptoids (56) to enhance vector stability. We studied further analogues of CyLoP-1 to 
evaluate the influence of the stereochemistry of the peptide backbone (enantiomeric purity of 
CyLoP-1 was about 95% as shown by GC-MS analysis on chiral phase) as well as the 
sequence alignment. Incorporation of D-amino acids and reversal of the sequence (inverse 
isomers) of the peptide is shown to increase the transmembrane delivery in the case of the Tat 
peptide (56). Therefore, the D-isomer [peptide 31] and L-inverse as well as D-inverse isomers 
of CyLoP-1 [peptide 32, peptide 33] were synthesized. Unexpectedly, these analogues 
showed reduced uptake by about 50% (Figure 29 A). In addition to the reduction in uptake, a 
decrease in diffuse cytoplasmic distribution was observed as compared to CyLoP-1 (Figure 
29 B). These results demonstrate that stereochemistry has a clear effect on cellular uptake of 
CyLoP-1. Unlike known CPPs, CyLoP-1 proved to be most efficient in its natural L-amino 
acid form. 
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Figure 29. Stereochemistry and sequence of CyLoP-1 affect its transport into cells 
and intracellular distribution. 3T3 cells were treated with 2.5 μM of different peptides for 18h in serum 
supplemented medium. A.) Cellular uptake was assessed by fluorescence spectroscopy after nuclear labeling 
and trypan quenching. B.) The same cells were subjected to fluorescence microscopy to evaluate intracellular 
distribution. The bar represents 20 μm. 
3.3.7 Effect of substitution of cysteines 
Next to truncated peptides, variety of peptides were synthesized by substitution of 
cysteines with α-amino-n-butyric acid (155) to study the combined effect of cysteine deletion 
and/or substitution [peptides 12-21]. This resulted in an immensely reduced cellular uptake to 
a level of 10% when compared to CyLoP-1 (Table 5). 
The significance of cysteines for internalization in peptide 1 (KMDCRWRWKCCKK) 
and peptide 4 (CyLoP-1, CRWRWKCCKK) was determined by substituting cysteine 
residues with Abu or serine (156). Substitution of one to three cysteine(s) by serine(s) in 
CyLoP-1 [peptides 22-27] revealed a positively correlated decrease in the uptake efficiency 
with the number of cysteines being replaced. Total exchange led to a nearly complete loss of 
activity (Figure 30). Similar results were obtained for Abu-substituted peptides. Furthermore, 
deleting single cysteine residues one by one [peptides 6-8] led to a decrease of uptake as well. 
Therefore, the number of cysteines in CyLoP-1 is vital for internalization and especially 
diffused cytosolic distribution. Replacement or deletion negatively affected uptake indicating 
that cysteines are substantial and could be involved in the mechanism of membrane 
penetration. 
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Figure 30. Cysteines are important for stereochemistry and affect its transport into 
cells and intracellular distribution. 3T3 cells were treated with 2.5 μM of different peptides for 18h in 
serum-supplemented medium. After treatment, cells were labeled with Hoechst 33342 followed by trypan 
quenching and rigorous HBSS washing. Cellular uptake was assessed by fluorescence spectroscopy, values are 
mean ± SEM, n = 3-6 each with six replicates. 
Tryptophan has been shown by others to participate in membrane permeation. They are 
reported to destabilize the membrane once the peptide is adhered to the surface. To examine 
these effects in CyLoP-1, replacement of either one or both tryptophans was investigated 
[peptides 28-30]. A decreased uptake (Table 5) and almost complete loss of diffusion was 
observed. Lowering of cytosolic distribution and uptake by substitution of tryptophan with 
phenylalanine (157) also signifies the substantial role played by the tryptophan residues. 
Results suggests the not only the presence but also the number of tryptophans are inevitable 
to maintain the required hydrophobicity and well functioning of CyLoP-1. 
3.3.8 Interaction of the cysteine-rich peptide with glutathione 
Apart from the cationic amino acids, CyLoP-1 contains three cysteine residues. To assess 
if these cysteines interact with the intracellular glutathione, cells were treated with various 
CyLoP-1 concentrations for 1, 4 and 18 h. A cysteine-deficient CPP, penetratin, was tested at 
similar concentrations and time points. No decrease in glutathione levels was observed at any 
of the tested concentrations (Fig. 31). Instead at all time points, a minor increase (5-10 %) 
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from the control values was obtained for CyLoP-1. As expected, penetratin also exhibited no 
interaction with intracellular glutathione. 
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Figure 31. Interaction of CyLoP-1 with cellular glutathione compared to penetratin. 
3T3 cells were labeled with different concentrations of CyLoP-1 or penetratin for various time points. The content 
of cellular glutathione was evaluated by MBBr assay followed by PI staining to estimate the cell number. 
3.3.9 CyLoP-1 delivers into various cell types 
To exclude that the distinguished cytosolic localization of CyLoP-1 is specific only for 
3T3 cells, cellular uptake was tested in other cell types. The chosen cell lines were from 
different origins, obtained from different tissues and other species. The human cervical 
cancer cell line, SHIN 3, displayed an intense diffuse fluorescence while the vesicles spread 
in the perinuclear region upon long term treatment with 2.5 µM of CyLoP-1 (Fig. 32). A 
similar diffuse uptake was observed in human pancreatic carcinoma cells, PANC-1, along 
with fluorescent vesiclular distribution in a restricted perinuclear region. This difference in 
the vesicular distribution was explained by the area occupied by the nucleus of different cell 
types. The fluorescent vesicles distributed in the cells according to the location of nucleus 
and availability of free cytoplasm. Differentiated mouse neuroblastoma N18 cells also 
showed a modest uptake of the peptide (Fig. 32). Cytsolic fluorescence was observed mainly 
in the cell bodies while the processes contained some fluorescent vesicles. However, C6 rat 
gliomas took up the peptide better and demonstrated bright diffuse fluorescence. Alike 3T3, 
all cell lines showed a heterogeneous distribution of diffuse fluorescence from CyLoP-1. The 
diffuse uptake was not detected in all cells, although vesicular uptake was seen in all. 
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Apart from these established cell lines, CyLoP-1 was proficiently taken up in primary 
cells derived from mouse bone marrow. In HSCs, the fluorescence was spread in the 
cytoplasm and also filled large vacuoles and small vesicles (Fig. 32). 
 
Figure 25. Intracellular localization of CyLoP-1 in various cell types. CyLoP-1 was applied 
to various cell types at the common concentration of 2.5 µM for 18 h. The labeling was performed in serum 
supplemented medium. Before microscopy, cells were stained with Hoechst 33342, quenched with trypan blue 
and extensively washed with HBSS. C6, SHIN-3 and Panc-1 were imaged at 40x magnification and N18 and 
HSCs at 63x. The bar represents 20 μm. 
3.4 Discussion 
Crotamine, a very basic toxin present in the venom of some species of the South 
American rattlesnake, was first identified by Goncalves and co-workers in early 1950’s (158). 
Since then this protein has been thoroughly investigated and characterized. However, in 2004 
Kerkis et al. identified a novel feature of crotamine where this protein was shown to 
successfully cross cellular membranes (145). Due to the chromosomal and centriole labeling 
properties of this toxin, it has a potential for use as a marker of actively proliferating cells and 
for the identification of cell stages. Focusing on the two ends of this 42 amino acids protein, 
Radis-Baptista and co-workers illustrated a shortened sequence combining residues 1-9 and 
38-42, that also localized in cellular nuclei after membrane translocation (159). 
Our primary interest was to develop a vector that could permeate the lipid bilayer and 
enter into the cytoplasm. In structure activity studies starting from one of the presumed NLS 
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sequence of crotamine (Crot27-39, KMDCRWRWKCCKK), a novel cysteine-rich peptide, 
namely CyLoP-1 (CRWRWKCCKK) was identified (146). The results of the present study 
demonstrate that CyLoP-1 is an efficient CPP with the ability to label cells at low micro-
molar concentrations. Unlike the complete toxin crotamine and the minimalist sequence 
studied by Radis-Baptista, CyLoP-1 did not show any karyophilic trait. In fact, the peculiar 
characteristic of our shortened sequence was the intense localization in the cytosol along with 
some vesicular uptake. Dispersed cytoplasmic fluorescence was observed after labeling cells 
for 4h with 5 μM of CyLoP-1 while lower concentrations needed elongated duration of 
incubation. The cytosolic distribution of CPPs in living cells is not very common and of late 
most of the conventional delivery peptides have been accounted for uptake by endocytosis 
(58, 110, 112, 131). The distribution into the cytosolic compartment has been reported for 
only some delivery vectors, worth mentioning are the cytoplasmic transduction peptide (160), 
S413 peptide (161), Rath peptide (162) and GALA peptide (163). Nevertheless, for all these 
CPPs and many more the distribution in the cytoplasm has been accounted for after fixation 
or following delivery assisted with other transport agents like Lipofectamine. 
CyLoP-1 not just efficiently labeled 3T3 cells but was also delivered into the cytoplasm 
of a variety of other cell types. The cytoplasmic localization of this peptide was not restricted 
to 3T3 cells. A similar distribution was observed in immortalized cell lines, tumour cells as 
well as in primary cells. Also the tissue of origin or the species of cell lines did not affect the 
intracellular distribution of CyLoP-1. This indicates the applicability of our peptide for 
delivery into a variety of cell types. However, the cells with large nucleus and limited 
cytosplasmic space like the cell bodies of differentiated neuroblastoma cells showed reduced 
cytosolic distribution. 
The uptake was compared to the internalization of well characterized CPPs, namely d-Tat 
i.e. HIV-1 Tat(49-57) with d-form of amino acids and penetratin. A striking difference was 
observed between the time course of CyLoP-1 and the other two standard CPPs in 3T3 cells. 
Our peptide showed the ability to transport into cells for prolonged durations, thus, 
potentially maximizing the amount of cargo delivered across the membrane. The cell-free 
stability studies supported the stability of the peptide in supplemented medium for these long 
hours. Furthermore, in our hands d-Tat and penetratin depicted mainly a vesicular distribution 
without any nuclear labeling. This could be justified due to the use of serum-supplemented 
medium for all uptake experiments. A cytosolic distribution of these standard CPPs has been 
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displayed by other groups, where studies at other time-points and concentrations were 
conducted in serum free conditions (58, 164). 
CyLoP-1 is a delivery vector obtained by shortening of a proposed nuclear localizing 
sequence (NLS) from the larger protein crotamine. In the minimization process, the main 
feature maintained was the ability to translocate cellular membranes and enter into cells. 
However, the uptake efficiency of CyLoP-1 decreased compared to the intact protein. 
Crotamine was reported to proficiently label cells at a concentration of 1 μM while CyLoP-1 
showed only a faintly detectable fluorescence at the same low dose. A concentration of 2.5 
μM was optimal for long-term labeling and 5 μM for short term. Refuting the suggestion for 
the sequence being a putative NLS, neither the original (Cro27-38) nor the shortened peptide 
depicted nuclear penetration and labeling. At all applicable concentrations and incubation 
times, CyLoP-1 showed vesicles distributed in the perinuclear area and diffuse fluorescence 
showed no overlapping with Hoechst labeling of nuclei. In addition, no centriole or 
chromosomal labeling by CyLoP-1 was observed at various cell stages. 
Negligible cytotoxicity was detected for CyLoP-1 up to 5 μM of labeling concentrations 
while higher concentrations showed increased toxicity. In addition, CyLoP-1 was not soluble 
at higher concentrations and showed precipitation. The results from the XTT assay as well as 
nuclear labeling by Hoechst were combined for a proper interpretation of toxicity. The XTT 
(like the MTT) assay, commonly used to determine cell viability, is detecting the cellular 
activity of reducing enzymes and is, thus, a measure of metabolic activity (165, 166). 
However, under certain conditions, cells can exhibit changed metabolic activity independent 
of the number of cells (167). For the incubation with 9 µM of CyLoP-1 an enhanced 
metabolic activity could be observed (Fig. 20) if the cell number normalized value was used. 
Here, the XTT value alone was indicating that there seemed to be any significant cytotoxic 
action of the conjugate at this concentration, whereas the Hoechst assay displayed a 30% 
reduction in the number of cells. Accordingly, an estimation of DNA or protein content and 
its correlation to the metabolic activity need to be done for appropriate assessment of induced 
toxicity. As a photometric assay based on the absorbance of the dye, an interference of 
remaining precipitate of CyLoP-1 on cells should also be taken into account which was 
observed at 9 µM. 
The incorporation of a quenching step with trypan blue in washing before evaluation of 
cellular delivery served as a supplement for toxicity verification. The dead cells could be 
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clearly identified as stained blue by this dye in bright-field microscopy. Besides, fluorescence 
microscopy detected low amounts of the trypan blue entering into partially compromised 
cells. Thus, trypan blue treatment avoided misinterpretation of uptake by quenching of extra-
cellular FITC fluorescence as well as allows toxicity elucidation by its red fluorescence 
(168). 
To consider the peptide for potential in vivo applications, an important factor that needs to 
be taken care of is the effect of serum. It has been reported that arginine-rich peptides 
transduce cell membranes directly when the uptake is performed in the absence of serum or 
in buffers like PBS (164). In contrast, the intracellular diffuse fluorescence was reduced when 
serum-supplemented medium was used. Interestingly, CyLoP-1 has a completely different 
behaviour regarding serum. This novel peptide has a good solubility in water but it requires 
serum for solubility in medium. Under serum-free conditions an insoluble precipitate was 
observed in solution that settled on cell surfaces. The precipitate stuck to external cell 
membranes and considerably low cellular delivery was obtained. A concentration of 10% 
serum in medium was sufficient for attaining a solubility of 5 μM of CyLoP-1. This 
obligation complicated the mechanistic investigation of uptake (as most chemical inhibitors 
are effective in serum-free conditions) but provides the opportunity to utilize CyLoP-1 for in 
vivo application. The interaction with serum proteins could perhaps elongate the half-life of 
this CDV as well. 
The internalization of CyLoP-1 might not exclusively involve endocytosis, as incubation 
of cells at low temperature did not completely abolish its uptake. A reduction of the 
fluorescence signal was observed after labeling cells at 4 ºC compared to 37 ºC. Fluorescence 
microscopy revealed that the vesicular transport considerably decreased at low temperature. 
On the other hand, the diffuse transport into the cytosolic compartment was maintained under 
the same labeling conditions. Due to the energy dependence, endocytosis could be the main 
pathway for vesicle-entrapped uptake of CyLoP-1. The diffuse distribution in the cytoplasm 
could be attributed to an alternate temperature-insensitive entry route. To understand this, the 
effect of the presence of various drugs like chloroquine, wortmannin, methyl-β-cyclodextrin, 
sodium azide, etc. that selectively inhibited selective pathways of cellular uptake processes 
was investigated. No interpretable conclusions could be drawn as all these analyses required 
the use of serum-free medium but serum was essential for solubility and delivery of CyLoP-1 
(data not shown). Another source of the diffuse fluorescence could be a re-distribution of the 
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endocytically taken up peptide after retrograde transport. It has been shown for crotamine that 
its cytotoxic effects involve lysosomal leakage which leads to a series of events resulting in 
cell death (169). 
Some peptides and proteins have been accounted for permeating cells by forming pores or 
disrupting the cell membrane (95, 143, 170). The membrane lytic activity of CyLoP-1 was 
evaluated and no indications of the rupture of the phospholipid bilayer were detected. 
Although, we did perceive that the peptide tends to initially bind cellular membranes and then 
permeate them. The membrane binding has been reported for other arginine rich CPPs (171-
174) as well as for the complete toxin crotamine (175). Plasma membrane-associated 
moieties, mainly heparin sulphate proteoglycans and glycosaminoglycans (53), interact with 
the guanidinium groups of arginines and assist the cationic peptides to bind in high amounts 
to the outer cell membrane. Thus local peptide concentrations are enhanced stimulating 
uptake of these peptides. As CyLoP-1 is also rich in arginines, a similar interaction with cell-
surface carbohydrates and proteins is likely. The SAR studies also highlighted the importance 
of tryptophan in the uptake and distribution of CyLoP-1. The involvement of tryptophan in 
membrane permeation has been reported for penetratin. 
Apart from arginines and lysines, a unique residue not very common in other CDVs but 
present in CyLoP-1 is cysteine. Due to problems linked with synthesis and short shelf-life of 
cysteine-containing peptides, we studied modifications of CyLoP-1 by removal or 
substitution of this sulphur-containing amino acid (146). Significant reductions in cellular 
delivery along with the removal of cytoplasmic localization of FITC lead to the maintenance 
of cysteines in CyLoP-1 (data not shown). Also the three disulfide bridges in crotamine have 
been hypothesized to be responsible for the unique penetration ability (145).  
The importance of the cysteine residues in CyLoP-1 for uptake and cytosolic distribution 
made us look for potential intracellular targets which might interact with these groups. Aside 
of proteins the most prominent cysteine-containing molecule inside cells is the tripeptide 
glutathione (γ-glutamylcysteinylglycine), an important intracellular reducing agent that 
participates in various decisive intracellular pathways (176-178) e.g. oxidative protection 
keeping the intracellular environment in a reduced state. Glutathione is directly involved in 
metabolic and transport functions, thus, amongst others causing the detoxification and 
inactivation of allogenic substances by conjugation (e.g. via mercapturic acid efflux pathway 
or direct excretion). To address if the amount of CyLoP-1 delivered into cells might have an 
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influence on these metabolic pathways, we assessed the effect on the glutathione content after 
labeling with various concentrations. No reduction was detected in the amount of glutathione 
even after long term incubations with CyLoP-1, thus verifying that at these concentrations 
this CPP did not significantly interact with glutathione and did not disturb the protective 
function of this tripeptide. Similar observation was made for the cysteine-free standard CPP 
penetratin. The small but not significant increase in glutathione content observed for CyLoP-
1 might be due to a direct interaction between the peptide’s cysteine groups and the reagent 
MBBr. 
In conclusion, CyLoP-1 is presented as a cysteine-rich CDV derived from crotamine that 
particularly delivers into the cytosolic compartment of cells. We hypothesize the involvement 
of two different mechanisms for the uptake of CyLoP-1: 1.) an endocytosis based mechanism 
that leads to the vesicular delivery of peptide, 2.) a supplementary direct membrane 
translocation by CyLoP-1 or a re-distribution after retrograde transport of endocytotically 
taken up peptide. Further detailed investigations at biophysical characterizatios are needed to 
confirm the exact uptake mechanism(s). Low threshold concentrations required for cellular 
labeling and transport maintained in the presence of serum recommend the application of 
CyLoP-1 for in vivo applications. This economically sustainable short deca-peptide could be 
utilized for intracellular delivery of biomolecules like therapeutics or imaging moieties 
directed to interact with targets located in the cytoplasm. Although with the current 
investigations it is premature to comment on the intracellular stability of CyLoP-1 and the 
cargo attached, yet delivery of desired cargo into cells and their release into cytosol is 
conceivable. Thus, with this peptide we present a novel delivery tool that efficiently evades 
entrapment into endosomal compartments. 
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Summary 
Noninvasive imaging techniques like MRI possess the prospective to observe molecular-
genetic and cellular processes. But the exogenously administered molecular imaging agents 
are unable to reach their molecular and cellular targets as the lipid bilayer of the cell poses a 
formidable natural barrier. However, a unique class of peptides known as cell penetrating 
peptides or CPPs has the ability to traverse this barrier and convey cargo molecules attached 
to it across the cell membrane. Thus the combination of CPPs with MR/optical agents would 
permit the evaluation of cellular processes through the interaction of imaging probes with 
intracellular targets like proteins, mRNA or DNA. 
In the first part of the thesis, two mRNA targeting MR based contrast agents were 
designed using the most efficiently transporting derivative of HIV-1 Tat. In vitro cell free 
studies depicted their ability to selectively bind to complementary oligonucleotide sequence. 
The agents also showed a significant MR contrast enhancement in labeled cells. However, no 
specific enrichment was observed in transgenic target containing cells. Some reasons 
hypothesized to reason the lack of specificity of these agents were the high non-specific 
binding of the non-sense sequence or the low sensitivity of MRI. But the primary cause could 
be the entrapment of most of the compound in vesicles, thus, hindering their interaction with 
specific mRNA. 
The second part of the thesis was based on the search for a CPP that could efficiently 
deliver cargos into the cytosol permitting there interaction with cytosolic targets like mRNA, 
proteins, etc. Extensive Structure Activity Relationship (SAR) studies were carried out on a 
putative nuclear localization sequence derived from the main toxin in snake venom. CyLoP-1 
was identified as a cysteine rich CPP with distinguished cytosolic diffusion as well as 
endosomal uptake at low concentrations. Further characterization of the biochemical 
properties and understanding of the unique intracellular localization of CyLoP-1 was 
performed. Our results indicate the involvement of two possible mechanisms. One is the 
endocytosis as reported for several other CPPs and the other could either be a direct delivery 
across membrane or a re-distribution after retrograde transport. Nevertheless, CyLoP-1 has 
potential for exploitation as a novel tool for cytosolic delivery of cargos. 
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